<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="61901"><DrugName>buparlisib</DrugName><DrugNamesKey><Name id="42971741">buparlisib</Name><Name id="43032202">buparlisib hydrochloride</Name></DrugNamesKey><DrugSynonyms><Name><Value>PI3K inhibitor (cancer), Novartis</Value></Name><Name><Value>phosphatidylinositol-3-kinase inhibitor (cancer), Novartis</Value></Name><Name><Value>NVP-BKM-120</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>BKM-120</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>BKM-210</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>buparlisib</Value><Types><Type>USAN</Type><Type>PINN</Type></Types></Name><Name><Value>buparlisib hydrochloride</Value><Types><Type>USAN</Type></Types></Name><Name><Value>phosphatidylinositol-3-kinase inhibitor (cancer), Adlai Nortye Biopharma</Value></Name><Name><Value>AN-2025</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>944396-07-0</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>1312445-63-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="23137">Novartis AG</CompanyOriginator><CompaniesPrimary><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company></CompaniesPrimary><CompaniesSecondary><Company id="23137">Novartis AG</Company></CompaniesSecondary><CrossReferences><SourceEntity id="61901" type="Drug"><TargetEntity id="683660" type="siDrug"></TargetEntity><TargetEntity id="458123" type="siDrug">Buparlisib</TargetEntity></SourceEntity><SourceEntity id="1111343" type="Company"><TargetEntity id="5046318644" type="organizationId">Adlai Nortye Biopharma Co Ltd</TargetEntity></SourceEntity><SourceEntity id="23137" type="Company"><TargetEntity id="4295890628" type="organizationId">Novartis AG</TargetEntity></SourceEntity><SourceEntity id="1705" type="ciIndication"><TargetEntity id="10014733" type="MEDDRA"/><TargetEntity id="D016889" type="MeSH"/><TargetEntity id="-49801714" type="omicsDisease"/><TargetEntity id="597" type="siCondition"/></SourceEntity><SourceEntity id="1744" type="ciIndication"><TargetEntity id="C83.1" type="ICD10"/><TargetEntity id="10061275" type="MEDDRA"/><TargetEntity id="D020522" type="MeSH"/><TargetEntity id="52416" type="ORPHANET"/><TargetEntity id="-1332546842" type="omicsDisease"/><TargetEntity id="1384" type="siCondition"/></SourceEntity><SourceEntity id="1745" type="ciIndication"><TargetEntity id="C82" type="ICD10"/><TargetEntity id="D008224" type="MeSH"/><TargetEntity id="-1402578461" type="omicsDisease"/><TargetEntity id="1742" type="siCondition"/></SourceEntity><SourceEntity id="1749" type="ciIndication"><TargetEntity id="C83.3" type="ICD10"/><TargetEntity id="10012818" type="MEDDRA"/><TargetEntity id="D016403" type="MeSH"/><TargetEntity id="544" type="ORPHANET"/><TargetEntity id="-308083648" type="omicsDisease"/><TargetEntity id="1741" type="siCondition"/></SourceEntity><SourceEntity id="2054" type="ciIndication"><TargetEntity id="10066476" type="MEDDRA"/><TargetEntity id="D019337" type="MeSH"/><TargetEntity id="-105358819" type="omicsDisease"/><TargetEntity id="1328" type="siCondition"/></SourceEntity><SourceEntity id="2436" type="ciIndication"><TargetEntity id="D75.81" type="ICD10"/><TargetEntity id="10028537" type="MEDDRA"/><TargetEntity id="D055728" type="MeSH"/><TargetEntity id="-1044236653" type="omicsDisease"/><TargetEntity id="1634" type="siCondition"/></SourceEntity><SourceEntity id="2454" type="ciIndication"><TargetEntity id="10018336" type="MEDDRA"/><TargetEntity id="D005909" type="MeSH"/><TargetEntity id="360" type="ORPHANET"/><TargetEntity id="-1357419475" type="omicsDisease"/><TargetEntity id="678" type="siCondition"/></SourceEntity><SourceEntity id="307" type="ciIndication"><TargetEntity id="10041823" type="MEDDRA"/><TargetEntity id="D002294" type="MeSH"/><TargetEntity id="-1612557995" type="omicsDisease"/><TargetEntity id="676" type="siCondition"/></SourceEntity><SourceEntity id="319" type="ciIndication"><TargetEntity id="10029547" type="MEDDRA"/><TargetEntity id="D008228" type="MeSH"/><TargetEntity id="547" type="ORPHANET"/><TargetEntity id="-1008757452" type="omicsDisease"/><TargetEntity id="703" type="siCondition"/></SourceEntity><SourceEntity id="3205" type="ciIndication"><TargetEntity id="10051066" type="MEDDRA"/><TargetEntity id="D046152" type="MeSH"/><TargetEntity id="44890" type="ORPHANET"/><TargetEntity id="-1743085733" type="omicsDisease"/><TargetEntity id="668" type="siCondition"/></SourceEntity><SourceEntity id="3246" type="ciIndication"><TargetEntity id="3031" type="siCondition"/></SourceEntity><SourceEntity id="3257" type="ciIndication"><TargetEntity id="10027480" type="MEDDRA"/><TargetEntity id="708" type="siCondition"/></SourceEntity><SourceEntity id="3657" type="ciIndication"><TargetEntity id="10055113" type="MEDDRA"/><TargetEntity id="589" type="siCondition"/></SourceEntity><SourceEntity id="3665" type="ciIndication"><TargetEntity id="10059515" type="MEDDRA"/><TargetEntity id="613" type="siCondition"/></SourceEntity><SourceEntity id="3673" type="ciIndication"><TargetEntity id="5572" type="siCondition"/></SourceEntity><SourceEntity id="427" type="ciIndication"><TargetEntity id="C53" type="ICD10"/><TargetEntity id="10008342" type="MEDDRA"/><TargetEntity id="D002583" type="MeSH"/><TargetEntity id="-837567682" type="omicsDisease"/><TargetEntity id="590" type="siCondition"/></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity><SourceEntity id="725" type="ciIndication"><TargetEntity id="1164" type="siCondition"/></SourceEntity><SourceEntity id="1575" type="Action"><TargetEntity id="465" type="Mechanism">Phosphatidylinositol 3-Kinase (PI3K) Inhibitors</TargetEntity><TargetEntity id="3512" type="Mechanism">Inositol Phosphate Kinase Inhibitors</TargetEntity></SourceEntity><SourceEntity id="61" type="Action"><TargetEntity id="885" type="Mechanism">Angiogenesis Inhibitors</TargetEntity></SourceEntity><SourceEntity id="1589" type="Action"><TargetEntity id="1062" type="Mechanism">Apoptosis Inducers</TargetEntity></SourceEntity><SourceEntity id="PTGT-01553" type="ciTarget"><TargetEntity id="59541" type="siTarget">Phosphatidylinositol 3-kinase (PI3K) (nonspecified subtype)</TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="C3">Phase 3 Clinical</PhaseHighest><RegulatoryDesignations><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation></RegulatoryDesignations><IndicationsPrimary><Indication id="1744">Mantle cell lymphoma</Indication><Indication id="1745">Follicle center lymphoma</Indication><Indication id="1749">Diffuse large B-cell lymphoma</Indication><Indication id="2054">Hematological neoplasm</Indication><Indication id="2436">Myelofibrosis</Indication><Indication id="307">Squamous cell carcinoma</Indication><Indication id="3673">Metastatic head and neck cancer</Indication></IndicationsPrimary><IndicationsSecondary><Indication id="1705">Endometrioid carcinoma</Indication><Indication id="2454">Glioblastoma</Indication><Indication id="319">Non-Hodgkin lymphoma</Indication><Indication id="3205">Gastrointestinal stromal tumor</Indication><Indication id="3246">Hormone refractory prostate cancer</Indication><Indication id="3257">Stage IV melanoma</Indication><Indication id="3657">Metastatic breast cancer</Indication><Indication id="3665">Metastatic non small cell lung cancer</Indication><Indication id="427">Uterine cervix tumor</Indication><Indication id="651">Cancer</Indication><Indication id="725">Solid tumor</Indication></IndicationsSecondary><ActionsPrimary><Action id="1575">Phosphoinositide 3-kinase inhibitor</Action></ActionsPrimary><ActionsSecondary><Action id="7293">Synergist</Action><Action id="695">Metastasis inhibitor</Action><Action id="62255">Anticancer protein kinase inhibitor</Action><Action id="61">Angiogenesis inhibitor</Action><Action id="1589">Apoptosis stimulator</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology><Technology id="586">Capsule formulation</Technology><Technology id="585">Oral formulation</Technology></Technologies><LastModificationDate>2019-05-28T06:34:50.000Z</LastModificationDate><ChangeDateLast>2019-05-30T00:00:00.000Z</ChangeDateLast><AddedDate>2008-11-20T11:23:01.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1111343" linkType="Company"&gt;Adlai Nortye Biopharma&lt;/ulink&gt;, under licence from &lt;ulink linkID="23137" linkType="Company"&gt;Novartis&lt;/ulink&gt;, is developing buparlisib (BKM-120; NVP-BKM-120; AN-2025), an oral phosphoinositide 3-kinase (PI3K) inhibitor which shows pro-apoptotic and antiangiogenic activity, for the potential treatment of  hematological cancer, primarily lymphoma;  and  head and neck squamous cell carcinoma (HNSCC)  [&lt;ulink linkID="1382787" linkType="Reference"&gt;1382787&lt;/ulink&gt;], [&lt;ulink linkID="1754142" linkType="Reference"&gt;1754142&lt;/ulink&gt;], [&lt;ulink linkID="2058132" linkType="Reference"&gt;2058132&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2019, a phase III clinical trial was underway in HNSCC patients  [&lt;ulink linkID="2130065" linkType="Reference"&gt;2130065&lt;/ulink&gt;]. In March 2014, a phase II trial was initiated in patients with Hormone Receptor-positive and negative breast cancer [&lt;ulink linkID="2154987" linkType="Reference"&gt;2154987&lt;/ulink&gt;]; in July 2017 the trial was completed [&lt;ulink linkID="2154987" linkType="Reference"&gt;2154987&lt;/ulink&gt;]. In December 2012, a phase Ib  trial in myelofibrosis began [&lt;ulink linkID="1383895" linkType="Reference"&gt;1383895&lt;/ulink&gt;]; in August 2016, the study was expected to complete in December 2018 [&lt;ulink linkID="1383895" linkType="Reference"&gt;1383895&lt;/ulink&gt;]. In February 2013, a phase II study began for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL) or follicular lymphoma (FL) [&lt;ulink linkID="1336715" linkType="Reference"&gt;1336715&lt;/ulink&gt;]; in December 2015, data were presented  [&lt;ulink linkID="1718445" linkType="Reference"&gt;1718445&lt;/ulink&gt;];  in July 2016, the study was expected to complete in December 2016 [&lt;ulink linkID="1336715" linkType="Reference"&gt;1336715&lt;/ulink&gt;]. In July 2018, Adlai planned to conduct combination trials of the drug with immune checkpoint inhibitors [&lt;ulink linkID="2052696" linkType="Reference"&gt;2052696&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The drug was previously in advanced development for breast cancer. In August 2012, a phase III combination trial (BELLE-2, + fulvestrant) was initiated in postmenopausal ER+/HER- advanced breast cancer in women refractory to aromatase inhibitor (AI) therapy (second line)  [&lt;ulink linkID="1336730" linkType="Reference"&gt;1336730&lt;/ulink&gt;]; in 2H15, mixed data were reported [&lt;ulink linkID="1678993" linkType="Reference"&gt;1678993&lt;/ulink&gt;], [&lt;ulink linkID="1698322" linkType="Reference"&gt;1698322&lt;/ulink&gt;], [&lt;ulink linkID="1721092" linkType="Reference"&gt;1721092&lt;/ulink&gt;].  In October 2012, a phase III combination study (BELLE-3, + fulvestrant) began in postmenopausal ER+/HER- advanced breast cancer in  women refractory to AI therapy and after progression on an mTOR inhibitor (third line) [&lt;ulink linkID="1307355" linkType="Reference"&gt;1307355&lt;/ulink&gt;].  In July 2014, Novartis expected to file for approval in breast cancer patients naive to mTOR inhibitors in 2015 and those previously treated with mTOR inhibitors in 2016 [&lt;ulink linkID="1578311" linkType="Reference"&gt;1578311&lt;/ulink&gt;]; however, by October 2015, Novartis was discussing data with regulators, and  deciding whether to file the drug or not; the company stated that overall survival data from BELLE-2, expected in   4Q16, would influence this decision [&lt;ulink linkID="1711376" linkType="Reference"&gt;1711376&lt;/ulink&gt;]. In January 2016, Novartis stated that discussions with regulatory bodies were ongoing and at that time planned filings for breast cancer patients naive to mTOR inhibitors and those previously treated with mTOR inhibitors in 2016 [&lt;ulink linkID="1739632" linkType="Reference"&gt;1739632&lt;/ulink&gt;]. In April 2016, however, Novartis no longer listed the drug as being in phase III development for breast cancer [&lt;ulink linkID="1754142" linkType="Reference"&gt;1754142&lt;/ulink&gt;]; in January 2017, Novartis confirmed it had discontinued development for second-line treatment of metastatic breast cancer hormone receptor-positive, aromatase inhibitor resistant/mTOR naive (plus fulvestrant), and third-line treatment of metastatic breast cancer hormone receptor-positive, aromatase inhibitor resistant/mTOR resistant (plus fulvestrant) [&lt;ulink linkID="1896505" linkType="Reference"&gt;1896505&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;The drug had also been developed for other breast cancer settings; a phase II/III trial (BELLE-4) in first-line breast cancer was initiated in August 2012 [&lt;ulink linkID="1513015" linkType="Reference"&gt;1513015&lt;/ulink&gt;]; negative data were presented in November 2015 and the company decided not to proceed to the phase III portion of the trial [&lt;ulink linkID="1711205" linkType="Reference"&gt;1711205&lt;/ulink&gt;]. A phase II trial in HER2-positive breast cancer in the neoadjuvant setting began in September 2013  [&lt;ulink linkID="1513024" linkType="Reference"&gt;1513024&lt;/ulink&gt;], however recruitment was suspended in October 2014 due to toxicity [&lt;ulink linkID="1721567" linkType="Reference"&gt;1721567&lt;/ulink&gt;]. A phase II trial began in triple negative breast cancer in June 2012; in October 2015, the trial was completed [&lt;ulink linkID="1587852" linkType="Reference"&gt;1587852&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Development in other cancer settings was previously undertaken. In June 2011, a phase II NSCLC trial began [&lt;ulink linkID="1200765" linkType="Reference"&gt;1200765&lt;/ulink&gt;]; in September 2014,   data were presented [&lt;ulink linkID="1597393" linkType="Reference"&gt;1597393&lt;/ulink&gt;]; in October 2014, the trial was completed [&lt;ulink linkID="1200765" linkType="Reference"&gt;1200765&lt;/ulink&gt;]. In June 2016, data from two further trials in NSCLC were presented; based on safety profiles in both studies and  the evolving treatment landscape, it was decided that buparlisib would not be further developed in lung cancer [&lt;ulink linkID="1786218" linkType="Reference"&gt;1786218&lt;/ulink&gt;]. In June 2012, a phase II trial in recurrent unresectable or metastatic cervical cancer was planned for January 2014, however the trial was withdrawn prior to recruitment [&lt;ulink linkID="1431819" linkType="Reference"&gt;1431819&lt;/ulink&gt;]. In February 2011, a phase II endometrial cancer study was initiated and in March 2014 it was completed [&lt;ulink linkID="1177993" linkType="Reference"&gt;1177993&lt;/ulink&gt;].  In June  2012, a phase I/II advanced melanoma trial was initiated [&lt;ulink linkID="1277046" linkType="Reference"&gt;1277046&lt;/ulink&gt;]. No recent development for these indications has been reported. In April 2012, a phase I gastrointestinal stromal tumor (GIST) trial was initiated; in  April 2016, the study was expected to complete in December 2016  [&lt;ulink linkID="1240245" linkType="Reference"&gt;1240245&lt;/ulink&gt;]. In September 2012, a phase Ib study of buparlisib in combination with &lt;ulink linkID="10309" linkType="Drug"&gt;abiraterone acetate&lt;/ulink&gt; in castration-resistant prostate cancer started [&lt;ulink linkID="1312374" linkType="Reference"&gt;1312374&lt;/ulink&gt;]; in July 2015, the trial completed  [&lt;ulink linkID="1312374" linkType="Reference"&gt;1312374&lt;/ulink&gt;]; in September 2015,  data were presented [&lt;ulink linkID="1702630" linkType="Reference"&gt;1702630&lt;/ulink&gt;]. In January 2014, a phase I/II trial of buparlisib in combination with &lt;ulink linkID="59953" linkType="Drug"&gt;capmatinib&lt;/ulink&gt; in glioblastoma was initiated; in July 2016, the trial was expected to complete in March 2017 [&lt;ulink linkID="1439804" linkType="Reference"&gt;1439804&lt;/ulink&gt;]; in November 2017, data were presented [&lt;ulink linkID="1987251" linkType="Reference"&gt;1987251&lt;/ulink&gt;].  In October 2013, a phase II trial in combination with &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; in metastatic head and neck cancer began [&lt;ulink linkID="1431818" linkType="Reference"&gt;1431818&lt;/ulink&gt;];  in August 2016, the trial was expected to complete in March 2017 [&lt;ulink linkID="1431818" linkType="Reference"&gt;1431818&lt;/ulink&gt;];  in June 2018, clinical data were  published [&lt;ulink linkID="2058384" linkType="Reference"&gt;2058384&lt;/ulink&gt;] [&lt;ulink linkID="2058132" linkType="Reference"&gt;2058132&lt;/ulink&gt;]. In July 2014, the company expected to file for  solid tumors in 2018 or later [&lt;ulink linkID="1578311" linkType="Reference"&gt;1578311&lt;/ulink&gt;]; in January 2016, filings for solid tumors were expected in 2020 or later [&lt;ulink linkID="1739632" linkType="Reference"&gt;1739632&lt;/ulink&gt;]; however, in January 2017, Novartis confirmed it had discontinued development for solid tumors [&lt;ulink linkID="1896505" linkType="Reference"&gt;1896505&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;Novartis is also developing &lt;ulink linkID="65353" linkType="Drug"&gt;alpelisib&lt;/ulink&gt;,  a PI3K-alpha  inhibitor for solid tumors.&lt;/para&gt;&lt;/Summary&gt;</value></Summary><PatentsAndGenerics><displayLabel>Patents and Generics</displayLabel><value>&lt;PatentsAndGenerics&gt;&lt;para&gt;The constraining product case is &lt;ulink linkID="PA3526787" linkType="Patent"&gt;WO-2007084786&lt;/ulink&gt;, which is published in the US as &lt;ulink linkID="PA5797687" linkType="Patent"&gt;US-08217035&lt;/ulink&gt;, expiry December 2027. &lt;/para&gt;&lt;/PatentsAndGenerics&gt;</value></PatentsAndGenerics><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;By July 2018,  buparlisib had received Fast Track designation from the FDA, presumably for head and neck squamous cell carcinoma [&lt;ulink linkID="2052696" linkType="Reference"&gt;2052696&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2014, Novartis expected to file for regulatory approval in solid tumors in 2018 or later [&lt;ulink linkID="1578311" linkType="Reference"&gt;1578311&lt;/ulink&gt;]. In January 2016, filings for solid tumors were expected in 2020 or later [&lt;ulink linkID="1739632" linkType="Reference"&gt;1739632&lt;/ulink&gt;]; this was still the case in July 2016 [&lt;ulink linkID="1781431" linkType="Reference"&gt;1781431&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2012, Novartis expected to file for regulatory approval in 2015 [&lt;ulink linkID="1283726" linkType="Reference"&gt;1283726&lt;/ulink&gt;]. In July 2014, Novartis expected to file for regulatory approval in breast cancer patients naive to mTOR inhibitors in 2015 and those previously treated with mTOR inhibitors in 2016 [&lt;ulink linkID="1578311" linkType="Reference"&gt;1578311&lt;/ulink&gt;]. In July 2015, Novartis planned to submit regulatory filings for the BKM120 + &lt;ulink linkID="3313" linkType="Drug"&gt;fulvestrant&lt;/ulink&gt; combination for the treatment of  ER+ AI resistant mTOR naive metastatic breast cancer and ER+ post AI and mTOR inhibitor metastatic breast cancer, in 2015 and 2016, respectively [&lt;ulink linkID="1679284" linkType="Reference"&gt;1679284&lt;/ulink&gt;]. However, by October 2015, Novartis was discussing data with regulators, and  deciding whether to file the drug or not; the company stated that overall survival data from BELLE-2, expected in   4Q16, would influence this decision [&lt;ulink linkID="1711376" linkType="Reference"&gt;1711376&lt;/ulink&gt;]. In January 2016, Novartis stated that discussions with regulatory bodies were ongoing and at that time planned filings for breast cancer patients naive to mTOR inhibitors and those previously treated with mTOR inhibitors in 2016 [&lt;ulink linkID="1739632" linkType="Reference"&gt;1739632&lt;/ulink&gt;]; however, in January 2017, Novartis confirmed it had discontinued development for second-line treatment of metastatic breast cancer hormone receptor-positive, aromatase inhibitor resistant/mTOR naive (plus fulvestrant), and third-line treatment of metastatic breast cancer hormone receptor-positive, aromatase inhibitor resistant/mTOR resistant (plus fulvestrant) [&lt;ulink linkID="1896505" linkType="Reference"&gt;1896505&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;&lt;subtitle&gt;Phase III&lt;/subtitle&gt;In March 2019, a phase III clinical trial was underway to evaluate buparlisib plus paclitaxel versus paclitaxel alone in refractory, recurrent or metastatic HNSCC patients who have progressed after prior platinum-based chemotherapy with or without prior anti-PD1/anti PDL1 antibody treatment (The BURAN Study) [&lt;ulink linkID="2130065" linkType="Reference"&gt;2130065&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;HER2-negative breast cancer&lt;/subtitle&gt;In October 2012, a multinational phase III, randomized, double-blind, placebo-controlled study (&lt;ulink linkID="88899" linkType="Protocol"&gt;NCT01633060&lt;/ulink&gt;; CBKM120F2303; BELLE-3) was initiated to evaluate the safety and efficacy of  buparlisib in combination with fulvestrant in postmenopausal women (estimated n = 615) with ER+/HER2- locally advanced or metastatic AI-refractory breast cancer that has also progressed on or after mTOR Inhibitor therapy (third line). The primary endpoint was PFS. At that time, enrollment was ongoing in Austria, and the study was scheduled to complete in October 2016 [&lt;ulink linkID="1307355" linkType="Reference"&gt;1307355&lt;/ulink&gt;]. By May 2015, enrollment was ongoing and this study was open in 21 countries [&lt;ulink linkID="1666068" linkType="Reference"&gt;1666068&lt;/ulink&gt;]; in June 2015, results were expected in 1H16 [&lt;ulink linkID="1671598" linkType="Reference"&gt;1671598&lt;/ulink&gt;]. In December 2016, further clinical data in 432 patients were presented at the 39th Annual San Antonio Breast Cancer Symposium in San Antonio, TX. The median PFS (primary endpoint) was 3.9 and 1.8 months in buparlisib and placebo groups, respectively. The overall response rate and clinical benefit rate (at 24 weeks) was achieved in 7.6 and 24.6% (buparlisib), 2.1 and 15.4% (placebo), respectively [&lt;ulink linkID="1890232" linkType="Reference"&gt;1890232&lt;/ulink&gt;]. In April 2017, further clinical data were presented at the 108th AACR Annual Meeting in Washington DC. In buparlisib + fulvestrant and placebo + fulvestrant groups, the median PFS was 4.2 and 1.6 (p &amp;lt; 0.001) , 4.7 and 1.4 (p &amp;lt; 0.001) and 4.1 and 1.4 months (p = 0.002) for ctDNA sample, tumor samples by PCR and tumor samples by NGS, respectively, with PIK3CA mutant , whereas, 3.9 and 2.7 (p = 0.026), 2.8 and 1.7 (p = 0.099), and 2.8 and 1.5 months (p = 0.086), respectively, with PIK3CA wild-type (secondary endpoint) [&lt;ulink linkID="1914166" linkType="Reference"&gt;1914166&lt;/ulink&gt;]. In October 2017, further clinical data were presented at the29th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Philadelphia, PA. In buparlisib + fulvestrant arm, PIK3CA altered patients showed improvement in progression free survival (hazard ratio (HR) = 0.44) compared to PIK3CA wild type patients (HR = 0.73) in PIK3CA altered and wild type patients, the median progression free survival (PFS) was 4.11 and 2.83 months, respectively, in buparlisib + fulvestrant arm; 1.4 and 1.48 months, respectively, in placebo arm. The improvements in PFS among patients with PIK3CA alternations did not extend to patients with alternations in other genes in the PI3K pathway (HR = 11) in buparlisib + fulvestrant arm. Among patients with alternations in 8q11.23 (HR = 0.90), no apparent PFS benefit was observed whereas patients with wild type 8q11.23 region reported PFS benefit with buparlisib + fulvestrant arm, respectively. Among RTKs, TP53, GATA3 and CDH1 genes, benefit of buparlisib + fulvestrant arm was similar [&lt;ulink linkID="1975571" linkType="Reference"&gt;1975571&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2012, a multinational phase III, randomized, double-blind, placebo-controlled study (&lt;ulink linkID="88058" linkType="Protocol"&gt;NCT01610284&lt;/ulink&gt;; CBKM120F2302; BELLE-2) was initiated, to evaluate the safety and efficacy of buparlisib in combination with fulvestrant in post-menopausal women (n = 1130, Chinese n = 47) with hormone receptor-positive HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer refractory to aromatase inhibitor therapy (second line). The primary endpoint was PFS. By October 2012, enrollment was ongoing in US, Canada and France. At that time, the trial was expected to complete in March 2017 [&lt;ulink linkID="1336730" linkType="Reference"&gt;1336730&lt;/ulink&gt;]. By October 2012, phase III development for breast cancer had started in Japan, presumably as part of this trial [&lt;ulink linkID="1338859" linkType="Reference"&gt;1338859&lt;/ulink&gt;]. In December 2013, trial BELLE-2 was initiated in China [&lt;ulink linkID="1629532" linkType="Reference"&gt;1629532&lt;/ulink&gt;]. By January 2015, the trial had also been started in Argentina, Australia, Belgium, Brazil, Czech Republic, Germany, Greece, Hungary, Israel, Italy, South Korea, Netherlands, Peru, Poland, Russia, Singapore, Slovakia, South Africa, Spain, Switzerland, Taiwan, Thailand and the UK  [&lt;ulink linkID="1336730" linkType="Reference"&gt;1336730&lt;/ulink&gt;]. In July 2015, Novartis reported that the trial met its primary endpoint, showing a significant improvement in PFS compared with fulvestrant alone.  In the overall study population, the observed improvement in PFS was described as 'relatively modest'; however, prospective analyses in certain predefined subgroups, including patients with PIK3CA mutation assessed in archival tumor samples and circulating tumor DNA, showed more significant and 'clinically meaningful' improvements. At that time, overall survival data were expected in 2H16 [&lt;ulink linkID="1678993" linkType="Reference"&gt;1678993&lt;/ulink&gt;], [&lt;ulink linkID="1698322" linkType="Reference"&gt;1698322&lt;/ulink&gt;]. Full data were reported at SABCS in November 2015. BELLE-2 met its primary endpoint in the full population (PFS 6.9 for buparlisib vs 5.0 months for placebo). Among patients with PIK3CA mutation, median PFS (7.0 vs 3.2), ORR (18 vs 4%) and CBR (47 vs 32%) were significantly improved for buparlisib+fulvestrant vs placebo+fulvestrant, but not in patients without the PIK3CA mutation (PFS 6.8 vs 6.8 months) [&lt;ulink linkID="1721092" linkType="Reference"&gt;1721092&lt;/ulink&gt;]. In December 2017, further data were presented at the 40th Annual San Antonio Breast Cancer Symposium in San Antonio, TX In the overall population, median OS favored buparlisib (33.2 months) versus placebo (30.4 months), although the statistical significance was not met (p = 0.045). In the main cohort, median OS favored buparlisib (30.9 months) versus placebo (28.9 months), although the statistical significance was not met (p = 0.144). In both arms, grade 3/4 adverse events were hyperglycemia, elevated ALT, nausea, elevated AST, diarrhea, fatigue, decreased appetite, depression, anxiety, stomatitis and asthenia, except for rash that occurred only in buparlisib arm [&lt;ulink linkID="1989770" linkType="Reference"&gt;1989770&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In August 2012, multicenter, randomized, double-blind, placebo-controlled, adaptive phase II/III study (BELLE-4; &lt;ulink linkID="86290" linkType="Protocol"&gt;NCT01572727&lt;/ulink&gt;) began to evaluate the efficacy and safety of buparlisib in combination with &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; in women (n= 524) with chemotherapy-naive, HER2-negative locally advanced or metastatic breast cancer. The primary endpoint was progression-free survival (PFS). At that time, interim analysis was expected at the end of phase II (at least 12 PFS), and the trial was to complete in December 2015 [&lt;ulink linkID="1513015" linkType="Reference"&gt;1513015&lt;/ulink&gt;].  In November 2015,  data were presented at the 27th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA. At the end of phase II portion, no improvement was observed in median PFS in the buparlisib versus placebo arm in either full population (8 versus 9.2 months) of PI3K pathway-activated sub-population (9.1 versus 9.2 months). The phase III portion of the trial was not initiated [&lt;ulink linkID="1711205" linkType="Reference"&gt;1711205&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase II&lt;/subtitle&gt;In March 2014, a randomized, parallel assignment, multicenter, double-blind, placebo-controlled, phase II study (&lt;ulink linkID="150506" linkType="Protocol"&gt;NCT01923168&lt;/ulink&gt;; CBYL719A2201; 2013-001862-41) of &lt;ulink linkID="65353" linkType="Drug"&gt;alpelisib&lt;/ulink&gt; or buparlisib plus &lt;ulink linkID="2784" linkType="Drug"&gt;letrozole&lt;/ulink&gt; in neoadjuvant treatment of postmenopausal women (n = 340) with hormone receptor-positive/HER2-, PIK3CA mutant or wild-type breast cancer was initiated [&lt;ulink linkID="2154987" linkType="Reference"&gt;2154987&lt;/ulink&gt;]. In May 2015, data were presented at the 51st ASCO meeting in Chicago, IL to determine an increase in pathologic clinical response and Objective Response Rate compared to treatment with placebo plus letrozole. Patients would receive alpelisib (300 mg qd) or buparlisib (100 mg qd or 5 days on and 2 days off intermittent regimen) plus letrozole (2.5 mg qd) in 28-day cycles. The pathological complete response at 24 weeks was the primary endpoint. At that time, global recruitment was ongoing and 71 sites (68 sites and 3 satellite sites) were open in 13 countries [&lt;ulink linkID="1666081" linkType="Reference"&gt;1666081&lt;/ulink&gt;], [&lt;ulink linkID="2154987" linkType="Reference"&gt;2154987&lt;/ulink&gt;]. In July 2017, the trial was completed [&lt;ulink linkID="2154987" linkType="Reference"&gt;2154987&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;  In May 2014, a randomized, parallel-assigned, phase II B-YOND trial (&lt;ulink linkID="172262" linkType="Protocol"&gt;NCT02058381&lt;/ulink&gt;; CBYL719XIC01) of the combination of &lt;ulink linkID="44314" linkType="Drug"&gt;tamoxifen&lt;/ulink&gt; plus &lt;ulink linkID="7286" linkType="Drug"&gt;goserelin acetate&lt;/ulink&gt; with &lt;ulink linkID="65353" linkType="Drug"&gt;BYL-719&lt;/ulink&gt; or buparlisib began in premenopausal patients (expected n = 192) with hormone receptor-positive/HER2-negative locally advanced or metastatic breast cancer  	in Hong Kong and Taiwan. At that time, the trial was expected to complete in August 2016 [&lt;ulink linkID="1534068" linkType="Reference"&gt;1534068&lt;/ulink&gt;]. In December 2014, it was reported at the  37th Annual San Antonio Breast Cancer Symposium in San Antonio, TX that the trial was to be amended to a phase Ib study to determine a recommended phase II dose, with preliminary efficacy findings to guide further development of the drug [&lt;ulink linkID="1620001" linkType="Reference"&gt;1620001&lt;/ulink&gt;]. In December 2015, further clinical data were presented at the 38th Annual San Antonio Breast Cancer Symposium in San Antonio, TX. The combination of buparlisib (100 mg) with tamoxifen and goserelin was less well tolerated. Significant toxicities included liver toxicity, psychiatric disorders, rash and hypertension [&lt;ulink linkID="1721656" linkType="Reference"&gt;1721656&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2012, a randomized, double-blind, placebo-controlled, phase II study (&lt;ulink linkID="86290" linkType="Protocol"&gt;NCT01572727&lt;/ulink&gt;) of buparlisib + paclitaxel was initiated in patients (estimated n = 200) with HER2-negative inoperable locally advanced or metastatic breast cancer, with or without PI3K pathway activation to evaluate the safety and efficacy. At that time, the study was expected to be complete by November 2014 [&lt;ulink linkID="1331389" linkType="Reference"&gt;1331389&lt;/ulink&gt;]. In October 2012, the study was ongoing [&lt;ulink linkID="1324993" linkType="Reference"&gt;1324993&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;HER2-positive breast cancer&lt;/subtitle&gt;In February 2017, a proof-of-concept, non-randomized	 phase II trial (&lt;ulink linkID="286777" linkType="Protocol"&gt;ISRCTN38635575&lt;/ulink&gt;: EUDRACT2015-003103-27, 20750) was to begin in the UK in patients (expected n=24) with HER2-positive breast cancer  with brain metastasis  to evaluate the effects of two-weeks preoperative therapy in April 2017. At that time, the trial was expected to complete in April 2019 [&lt;ulink linkID="1897691" linkType="Reference"&gt;1897691&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2013, a randomized, double-blind, placebo-controlled, phase II study (NeoPHOEBE; &lt;ulink linkID="117135" linkType="Protocol"&gt;NCT01816594&lt;/ulink&gt;) began to evaluate buparlisib in combination with trastuzumab and paclitaxel in women with HER2-positive primary breast cancer prior to definitive surgery. The primary endpoint was pathologic complete response rate compared to placebo plus trastuzumab and weekly paclitaxel. Patients received continuous daily buparlisib or placebo in combination with trastuzumab and weekly paclitaxel for 12 weeks. The trial was to enroll 220 patients in 11 countries, and complete in February 2016 [&lt;ulink linkID="1513024" linkType="Reference"&gt;1513024&lt;/ulink&gt;]. However recruitment was terminated in October 2014 due to toxicity [&lt;ulink linkID="1721567" linkType="Reference"&gt;1721567&lt;/ulink&gt;]. In December 2015, clinical data were presented at the 38th Annual San Antonio Breast Cancer Symposium in San Antonio, TX. Serious adverse events were reported in nine patients including three patients with hepatotoxicity. Of 14 patients who developed grade 3 to 4 liver enzyme elevation, 9 recovered to at least grade 1 [&lt;ulink linkID="1721567" linkType="Reference"&gt;1721567&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2010, a phase Ib/II, non-randomized, open-label, parallel-group study (&lt;ulink linkID="66771" linkType="Protocol"&gt;NCT01132664&lt;/ulink&gt;; CBKM120X2107) was initiated in the US and Spain to evaluate the safety and efficacy of buparlisib in combination with &lt;ulink linkID="6386" linkType="Drug"&gt;trastuzumab&lt;/ulink&gt; in patients (estimated n = 70) with relapsing HER2-overexpressing metastatic breast cancer who had previously failed trastuzumab. Enrollment was ongoing in September 2011, and the study was scheduled to complete in June 2014 [&lt;ulink linkID="1230847" linkType="Reference"&gt;1230847&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Triple negative breast cancer&lt;/subtitle&gt;In June 2012, an open-label phase II trial (&lt;ulink linkID="88756" linkType="Protocol"&gt;NCT01629615&lt;/ulink&gt;) began in patients with metastatic triple negative breast cancer who have progressed after standard chemotherapy in the adjuvant or metastatic settings. The primary outcome was rate of clinical benefit. The trial was to enroll 50 patients and complete in June 2016. In October 2015, the trial was completed [&lt;ulink linkID="1587852" linkType="Reference"&gt;1587852&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Phase I&lt;/subtitle&gt;In June 2012, a  non-randomized, open-label, single-group phase I study (&lt;ulink linkID="88673" linkType="Protocol"&gt;NCT01626209&lt;/ulink&gt;; CBKM120Z2102)  &lt;ulink linkID="61901" linkType="Drug"&gt;&lt;/ulink&gt;of  BKM-210 at 80 mg/day began in adult Chinese patients with advanced breast cancer. In October 2012, the  study was expected to be complete by September 2013 [&lt;ulink linkID="1385489" linkType="Reference"&gt;1385489&lt;/ulink&gt;]. In September 2013,  data were presented from 24 patients at the 2013 European Cancer Congress in Amsterdam, the Netherlands. The 100 mg/day dose was established as the MTD (primary endpoint).  Of the 13 patients evaluable, 5 patients had stable disease and 8 patients had progressive disease [&lt;ulink linkID="1481429" linkType="Reference"&gt;1481429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2011, a phase I study (&lt;ulink linkID="76669" linkType="Protocol"&gt;NCT01339442&lt;/ulink&gt;; 201105445; NCI-2011-00583) of BKM-210 in combination with fulvestrant in postmenopausal patients (n = 22) with estrogen receptor-positive stage IV breast cancer began. It was estimated the study would  finish in September 2013 [&lt;ulink linkID="1307339" linkType="Reference"&gt;1307339&lt;/ulink&gt;]. In June 2012, it was reported that  enrollment into starting does of 80 mg po qd buparlisib/500 mg fulvestrant on days 1 and 15, had completed  and dose level 2 (100 mg po qd buparlisib and same fulvestrant dose, was enrolling  [&lt;ulink linkID="1295969" linkType="Reference"&gt;1295969&lt;/ulink&gt;]. In December 2013, data were presented at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium, in San Antonio, TX. Of 11 patients evaluable for response, there were 5 prolonged stable diseases for at least 6 cycles and 1 partial response. Adverse events relating to dose reduction/interruption included asymptomatic ALT elevations, grade 2 confusion, grade 2 hyperglycemia and grade 3 rash.  At that time, 8 patients were still receiving treatment [&lt;ulink linkID="1512921" linkType="Reference"&gt;1512921&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Glioblastoma&lt;/subtitle&gt;In January 2014, a non-randomized, open-label, single group assignment, phase I/II  study (&lt;ulink linkID="137824" linkType="Protocol"&gt;NCT01870726&lt;/ulink&gt;; CINC280X22040) of the safety and efficacy of &lt;ulink linkID="59953" linkType="Drug"&gt;capmatinib&lt;/ulink&gt; in combination with buparlisib, and of single-agent capmatinib, in patients (expected n  = 60) with recurrent glioblastoma with PTEN mutations, homozygous deletion of PTEN or PTEN negative began in the US and Europe. In the combination arm, a maximum of 10 patients, who had previously received &lt;ulink url="bevacizumab"&gt;bevacizumab&lt;/ulink&gt; treatment, would be enrolled in the phase II part. The study was expected to complete in 	October 2016. In July 2016, the trial was ongoing and expected to complete in March 2017 [&lt;ulink linkID="1439804" linkType="Reference"&gt;1439804&lt;/ulink&gt;]. In November 2017, clinical data were presented at the 22nd Annual Scientific Meeting of the Society for Neuro-Oncology in San Francisco, CA. In phase Ib portion, nausea, personality change, and elevated transaminases were the DLTs. MTD was determined to be INC-280 300 mg bid + BKM-120 80 mg qd. Recommended phase II dose was not determined due to poor tolerability; a drug-drug interaction resulting in low BKM-120 exposure; and no strong evidence of activity. In the INC-280 monotherapy arm (n = 10), the most common INC280-related adverse events (all grades) were nausea and fatigue. Stable disease as best response was observed in three patients [&lt;ulink linkID="1987251" linkType="Reference"&gt;1987251&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2011, two-stage, multicenter, open label, dose-escalation a phase I trial ((&lt;ulink linkID="82465" linkType="Protocol"&gt;NCT01473901&lt;/ulink&gt;; CBKM120E2101;2011-001157-87)  of buparlisib  plus adjuvant &lt;ulink linkID="4529" linkType="Drug"&gt;temozolomide&lt;/ulink&gt; and with concomitant radiation therapy and temozolomide in newly diagnosed glioblastoma patients was initiated in the US Australia, Canada and Spain. At that time the trial was expected to be completed in May [&lt;ulink linkID="1331781" linkType="Reference"&gt;1331781&lt;/ulink&gt;]. In September 2012, the study was reported to be ongoing at the at the 37th European Society for Medical Oncology Congress in Vienna, Austria [&lt;ulink linkID="1324986" linkType="Reference"&gt;1324986&lt;/ulink&gt;]. In November 2015, further clinical data were presented at the 20th Annual Scientific Meeting of the Society for Neuro-oncology in San Antonio, TX. In the concomitant phase (n = 22), buparlisib was administered at two schedules: 60/40 mg qd or 40 mg days 1 to 5/q7d, in combination with RT (2.5 Gray/day) + temozolomide (75 mg/m2/day) over 42 days. In the adjuvant phase (n = 16), buparlisib was administered at 80 mg/qd during cycle 1 with temozolomide (150 mg/m2, days 1 to 5/q28d; A1), and at 60/80 mg/qd during cycles 2 to 12 with temozolomide (200 mg/m2) on days 1 to 5/q28d (A2). Of 16 adjuvant patients treated, six developed DLTs, including three DLTs in A1: Grade 3-hyperglycemia, anxiety and intermittent confusion (n = 1 each) at 80 mg/qd; and three in A2: grade 2-hyperglycemia (n = 1) at 60 mg/qd, grade 4-platelet count decrease and thrombocytopenia (n = 1 each) at 80 mg/qd. Of 22 concomitant patients treated, seven developed DLTs: grade 4-thrombocytopenia (n = 2) at 60 mg/qd, lipase elevation (n = 2) and grade 2 thrombocytopenia (n = 1) at 40 mg/qd, grade 3 decreased mood (n = 1) and grade 4 decreased platelet count (n = 1) at 40 mg days 1 to 5/q7d. Overall, the recommended phase II dose (RP2D) of buparlisib for the adjuvant phase in combination with temozolomide was defined as 80 mg/qd [&lt;ulink linkID="1726242" linkType="Reference"&gt;1726242&lt;/ulink&gt;]. In May 2017, the trial was ongoing but not recruiting patients [&lt;ulink linkID="1331781" linkType="Reference"&gt;1331781&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In May 2011, an investigator-led, non-randomized, open-label, phase II study (&lt;ulink linkID="76665" linkType="Protocol"&gt;NCT01339052&lt;/ulink&gt;; CBKM120XUS07T) was initiated in patients with recurrent glioblastoma (expected n = 65) in the US, to assess the safety and efficacy of buparlisib. The study was expected to be complete by May 2012 [&lt;ulink linkID="1195391" linkType="Reference"&gt;1195391&lt;/ulink&gt;].  In June 2013, data were presented at the 49th ASCO meeting in Chicago, IL.  Buparlisib was well tolerated. At 100 mg, buparlisib was found to achieve intratumoral concentrations which were adequate to inhibit PI3K pathway. At that time, 9 patients were enrolled in part 1 and 61 were enrolled in part 2, and the patient accrual was ongoing [&lt;ulink linkID="1426094" linkType="Reference"&gt;1426094&lt;/ulink&gt;]. In November 2013, similar data were presented at the combined 4th Quadrennial Meeting of the World Federation of Neuro-Oncology and 18th Annual Scientific Meeting of the Society for Neuro-Oncology in San Francisco CA [&lt;ulink linkID="1529084" linkType="Reference"&gt;1529084&lt;/ulink&gt;]. In June 2016, the trial was ongoing. At that time, the study was expected to complete in October 2016 [&lt;ulink linkID="1195391" linkType="Reference"&gt;1195391&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Endometrial cancer&lt;/subtitle&gt;In February 2011, an open-label, phase II study (&lt;ulink linkID="74420" linkType="Protocol"&gt;NCT01289041&lt;/ulink&gt;; CBKM120C2201) was initiated in patients with advanced endometrial carcinoma (expected n = 140) in the US, Europe and Singapore, to assess the safety and efficacy of buparlisib. The study was completed in March 2014 [&lt;ulink linkID="1177993" linkType="Reference"&gt;1177993&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-small-cell lung cancer&lt;/subtitle&gt;In June 2016, clinical data from a phase Ib/II study (BASALT-3; &lt;ulink linkID="148186" linkType="Protocol"&gt;NCT01911325&lt;/ulink&gt;) to evaluate the safety and efficacy of buparlisib in 27 patients with squamous NSCLC were presented at the 52nd ASCO meeting in Chicago, IL. Patients received buparlisib 80 or 100 mg/day with q3w docetaxel 75 mg/m2. DLTs were grade 3 asthenia (n = 1) and grade 2 mood altered (n = 1) with 80 mg; and grade 4 neutropenia (n = 1), grade 2 and grade 3 hyperglycemia (n = 1 each) with 100 mg buparlisib treatment. MTD was found to be 80 mg buparlisib + docetaxel. At both dose levels, median progression-free survival was 2.8 months. Overall response rate  was 6 and 18% at 80 and 100 mg, respectively. Treatment was discontinued by all patients; most frequently due to disease progression  [&lt;ulink linkID="1786218" linkType="Reference"&gt;1786218&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2013, a randomized, double-blind, single-group assignment, phase I/II trial (&lt;ulink linkID="118135" linkType="Protocol"&gt;NCT01820325&lt;/ulink&gt;; CBKM120D2204; 2012-005541-21; BASALT-2) to evaluate &lt;ulink linkID="44383" linkType="Drug"&gt;carboplatin&lt;/ulink&gt; and &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; with or without buparlisib began in patients (expected n = 220) in the US, Australia, Canada, Spain and Turkey with previously untreated metastatic squamous NSCLC. The primary endpoints were number of DLTs over 21 days and PFS assessed using RECIST 1.1 up to 3 years or until first progression. However, by May 2016, the trial had been terminated [&lt;ulink linkID="1431815" linkType="Reference"&gt;1431815&lt;/ulink&gt;]. In June 2016, further clinical data from six patients were presented at the 52nd ASCO meeting in Chicago, IL. Among three evaluable patients, two reported DLTs of grade 3 stomatitis and grade 4 neutropenia (n = 1 each). Partial response (PR) was observed in one patient, and stable disease in three patients. Patient decision was the most common primary reason for treatment discontinuation [&lt;ulink linkID="1786218" linkType="Reference"&gt;1786218&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2011,  a randomized, open-label, phase II  study (&lt;ulink linkID="74799" linkType="Protocol"&gt;NCT01297491&lt;/ulink&gt;; CBKM120D2201; BASALT-1) was initiated in patients with  NSCLC (expected n = 180) in North America, South America, Europe,Taiwan and China, to assess the safety and efficacy of buparlisib compared to docetaxel or &lt;ulink linkID="3536" linkType="Drug"&gt;pemetrexed&lt;/ulink&gt;. In October 2012, the study was scheduled to be complete by  April 2013  [&lt;ulink linkID="1200765" linkType="Reference"&gt;1200765&lt;/ulink&gt;]. In September 2014,  clinical data were presented from 40 patients at the 39th European Society for Medical Oncology congress in Madrid, Spain. At week 12, the respective PFS rate (primary endpoint) was 23.3 and 20% for the squamous and non- squamous groups.  Overall, the futility criterion in stage 1 (PFS rate &amp;lt; 50% at 12 weeks) was met in both histology groups 									 [&lt;ulink linkID="1597393" linkType="Reference"&gt;1597393&lt;/ulink&gt;]. In October 2014, the trial was completed [&lt;ulink linkID="1200765" linkType="Reference"&gt;1200765&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Prostate cancer&lt;/subtitle&gt;In June 2016, clinical data from an investigator-led, prospective, phase II study (&lt;ulink linkID="92952" linkType="Protocol"&gt;NCT01695473&lt;/ulink&gt;) which evaluated the pharmacodynamic effect of buparlisib in 11 men with prostate cancer were presented at the 52nd ASCO meeting in Chicago, IL. Men were treated with buparlisib (100 mg, daily) for 14 days prior to radical prostatectomy (RP). Decrease (&amp;gt;/= 60%) in phosphorylated S6, pAKT, and p4EBP1 immunohistochemistry (IHC) from baseline was reported in 7, 7 and 10 patients, respectively. Overall, buparlisib demonstrated pharmacodynamic efficacy by significant downstream target inhibition of the P13K pathway. The study was terminated in September 2015 due to lack of accrual [&lt;ulink linkID="1769993" linkType="Reference"&gt;1769993&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In July 2015, an investigator-led, open-label, non-randomized, single group assigned, dose finding, efficacy, phase Ib trial (&lt;ulink linkID="234150" linkType="Protocol"&gt;NCT02487823&lt;/ulink&gt;; NCMPC-BKM-IPC 2012-009), was initiated in France, in patients (expected n = 18), with non castrate metastatic prostate cancer, in combination with suprefact) and bicalutamide. At that time, the trial was expected to be completed in October 2015 [&lt;ulink linkID="1677081" linkType="Reference"&gt;1677081&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2014, an open-label, single group assigned, phase II trial (&lt;ulink linkID="167307" linkType="Protocol"&gt;NCT02035124&lt;/ulink&gt;, SCRI GU 79) was initiated in the US, to evaluate safety and efficacy of BKM-120 along with &lt;ulink linkID="28035" linkType="Drug"&gt;cabazitaxel&lt;/ulink&gt; in patients (expected n = 49) with advanced prostate cancer. However, in January 2015, the trial was withdrawn prior to enrollment [&lt;ulink linkID="1742723" linkType="Reference"&gt;1742723&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011, an investigator-led, open-label, phase II study (&lt;ulink linkID="78813" linkType="Protocol"&gt;NCT01385293&lt;/ulink&gt;; Pro00027410) was initiated in patients with metastatic castration-resistant prostate cancer (expected n = 66) in the US, to assess the safety and efficacy of buparlisib. At that time, the study was scheduled to complete in December 2016 [&lt;ulink linkID="1230254" linkType="Reference"&gt;1230254&lt;/ulink&gt;]. In May 2015, data from the trial were presented at the 51st ASCO meeting in Chicago, IL. Futility was met due to short median PFS and low rates of PFS. Data demonstrated that PFS was not improved with BKM-120 as monotherapy or in combination with &lt;ulink linkID="53981" linkType="Drug"&gt;enzalutamide&lt;/ulink&gt; [&lt;ulink linkID="1662214" linkType="Reference"&gt;1662214&lt;/ulink&gt;].  In November 2015, the trial was ongoing. At that time, the trial was expected to complete in December 2016 [&lt;ulink linkID="1230254" linkType="Reference"&gt;1230254&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, a phase Ib, non-randomized, parallel-group, open-label study (&lt;ulink linkID="88955" linkType="Protocol"&gt;NCT01634061&lt;/ulink&gt;; CBEZ235D2101, 2012-002250-23) was planned in North America and the EU, to evaluate the safety and efficacy of &lt;ulink linkID="57048" linkType="Drug"&gt;dactolisib&lt;/ulink&gt; (200, 300, and 400 mg bid) versus buparlisib (60, 80, and 100 mg qd po), both in combination with &lt;ulink linkID="10309" linkType="Drug"&gt;abiraterone acetate&lt;/ulink&gt; (1000 mg po qd), in patients (estimated n = 122) with CRPC. The primary endpoints included incidence of DLTs in cycle 1 and prostate specific antigen decline &amp;gt;/= 30%. At that time, the study was expected to commence in August 2012 and scheduled to complete in March 2015. In September 2012, the trial was recruiting in Canada. The trial completed in July 2015  [&lt;ulink linkID="1312374" linkType="Reference"&gt;1312374&lt;/ulink&gt;]. In September 2015, data  from the trial in patients (n = 43) with castration-resistant prostate cancer were presented at the 2015 European Cancer Congress in Vienna, Austria. In the dose-escalation (n = 25 and 18, respectively) and dose expansion (n = 40 and 40, respectively) phases, patients received buparlisib (60 and 100 mg qd) or dactolisib (200 mg bid) in combination with fixed-dose abiraterone acetate (1000 mg qd) and prednisone (5 mg bid) on a continuous schedule of 28-day cycles. The best overall (radiologic) responses such as stable disease and non-complete response or non-progressive disease were achieved by 4 and 8 patients with measurable and non-measurable disease, respectively [&lt;ulink linkID="1702630" linkType="Reference"&gt;1702630&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Transitional cell carcinoma&lt;/subtitle&gt;In March 2012, an open-label, phase II study (&lt;ulink linkID="85562" linkType="Protocol"&gt;NCT01551030&lt;/ulink&gt;; 11-060) led by &lt;ulink linkID="22122" linkType="Company"&gt;Memorial Sloan Kettering Cancer Center&lt;/ulink&gt; was initiated in patients with advanced transitional cell carcinoma of the urothelium (expected n = 35) in the US, to assess the safety and efficacy of buparlisib. At that time, the study was scheduled to complete in March 2014 [&lt;ulink linkID="1271589" linkType="Reference"&gt;1271589&lt;/ulink&gt;]. In February 2015, clinical data were presented at the ASCO Genitourinary Cancers Symposium in Orlando, FL. The median progression free survival was 2.77 months. At 2 months, six patients had stable disease and one patient had partial response [&lt;ulink linkID="1637895" linkType="Reference"&gt;1637895&lt;/ulink&gt;]. In December 2015, the trial was ongoing  [&lt;ulink linkID="1271589" linkType="Reference"&gt;1271589&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Myelofibrosis&lt;/subtitle&gt;In December 2012, an open-label, multicenter, two-arm, dose-finding phase Ib trial (&lt;ulink linkID="98882" linkType="Protocol"&gt;NCT01730248&lt;/ulink&gt;; CINC424A2104) was initiated in patients (expected n = 62)   with primary myelofibrosis (PMF), postpolycythemia vera-myelofibrosis (PPV-MF), or post-essential thrombocythemia-myelofibrosis (PET-MF) in  Germany to evaluate the safety of the combination of &lt;ulink linkID="54662" linkType="Drug"&gt;ruxolitinib&lt;/ulink&gt; and buparlisib in the myelofibrosis population and to establish the maximum tolerated dose and or the recommended phase II dose of the combination. The study was expected to   complete in June 2015. By February 2013,  recruitment  had yet to begin in Australia, Israel, Singapore  and several Euorpean sites [&lt;ulink linkID="1383895" linkType="Reference"&gt;1383895&lt;/ulink&gt;]. In December 2014, clinical data were presented from this study (HARMONY) in 20 JAK inhibitor–naive patients and 13 patients who did not benefit from prior JAK inhibition  at the 56th ASH Meeting in San Francisco, CA. The recommended phase II dose  was 15 mg ruxolitinib bid + 60 mg buparlisib qd. Pharmacokinetic parameters of ruxolitinib were found to be comparable when administered alone or in combination with buparlisib. The combination therapy was well tolerated, with early signs indicating promising efficacy even in patients who have previously failed with JAK inhibitors [&lt;ulink linkID="1618727" linkType="Reference"&gt;1618727&lt;/ulink&gt;].  In December 2015, further clinical data were presented at the 57th ASH Annual Meeting and Exposition in Orlando, FL. Overall, five and three patients in arms A and B discontinued due to AEs and three deaths were reported at MTD in arm B. Percentage of patients able to achieve &amp;gt;/= 50% reduction in palpable spleen length and at MTD from baseline was 51.5 and 54.52058132, respectively in arm A and 26.7 and 20, respectively in arm B [&lt;ulink linkID="1718398" linkType="Reference"&gt;1718398&lt;/ulink&gt;]. In August 2016, the trial was ongoing but not recruiting and at that time, the study was expected to complete in December 2018 [&lt;ulink linkID="1383895" linkType="Reference"&gt;1383895&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Melanoma&lt;/subtitle&gt;In June 2012, an open-label, phase I/II study (&lt;ulink linkID="84145" linkType="Protocol"&gt;NCT01512251&lt;/ulink&gt;; Protocol 11952) was initiated in the US,  to assess the safety and efficacy of buparlisib in combination with &lt;ulink linkID="54469" linkType="Drug"&gt;vemurafenib&lt;/ulink&gt; in patients (expected n = 46) with BRAFV600E/K-mutant advanced melanoma. At that time, the study was scheduled to complete in June 2015 [&lt;ulink linkID="1277046" linkType="Reference"&gt;1277046&lt;/ulink&gt;]. In May 2014, data were presented at the 50th ASCO meeting in Chicago, IL. Treatment with BKM-120 along with vemurafenib was poorly tolerated [&lt;ulink linkID="1560486" linkType="Reference"&gt;1560486&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Gastrointestinal stromal tumor&lt;/subtitle&gt;In April 2011, a non-randomized, open-label, phase I study (&lt;ulink linkID="82227" linkType="Protocol"&gt;NCT01468688&lt;/ulink&gt;; CSTI571X2101) was initiated in the US, Canada, Japan and Europe for patients with unresectable or metastatic GIST who had failed &lt;ulink linkID="11460" linkType="Drug"&gt;imatinib&lt;/ulink&gt; or &lt;ulink linkID="12973" linkType="Drug"&gt;sunitinib&lt;/ulink&gt; therapy (expected n = 50), to assess the safety and efficacy of third-line buparlisib in combination with imatinib. In  April 2016, a total of 60 patients had enrolled. At that time, the study was ongoing  and it was expected to complete in December 2016 [&lt;ulink linkID="1240245" linkType="Reference"&gt;1240245&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Colorectal cancer&lt;/subtitle&gt;In September 2012, results were presented from a phase I trial by &lt;ulink linkID="20597" linkType="Company"&gt;University of Kansas&lt;/ulink&gt; of buparlisib plus &lt;ulink linkID="2871" linkType="Drug"&gt;irinotecan&lt;/ulink&gt; in metastatic colorectal cancer patients were presented at the 37th European Society for Medical Oncology Congress in Vienna, Austria. The 50 mg buparlisib plus 120/150 mg/m2 irinotecan was found to be tolerated and MTD (primary objective) was not reached. Buparlisib (50 mg) co-administration showed no significant effect on irinotecan (150 mg/m2) disposition in five of six patients. In one patient, buparlisib co-administration resulted in markedly higher Cmax and AUC of irinotecan (150 mg/m2) but no change in half-life. Overall, buparlisib showed no significant and consistent effect on the irinotecan disposition [&lt;ulink linkID="1325329" linkType="Reference"&gt;1325329&lt;/ulink&gt;]. In September 2014, final results were  presented at the 39th European Society for Medical Oncology congress in Madrid, Spain.    Of the 4 patients who received 4 cycles of therapy 2 patients, each had stable and progressive disease. There were no objective responses observed. Nausea, vomiting, diarrhea, fatigue, hyperglycemia, and transaminitis were the most common adverse events. The MTD was determined to be irinotecan 150 mg/m2 + buparlisib 50 mg/day [&lt;ulink linkID="1597619" linkType="Reference"&gt;1597619&lt;/ulink&gt;]. In November 2015, the trial (&lt;ulink linkID="75032" linkType="Protocol"&gt;NCT01304602&lt;/ulink&gt;; 12480) was ongoing. At that time, the study (expected n = 30) was expected to complete in January 2016 [&lt;ulink linkID="1780733" linkType="Reference"&gt;1780733&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Head and neck cancer&lt;/subtitle&gt;In  May 2013, a randomized, double-blind, parallel-assignment, phase II trial (&lt;ulink linkID="130168" linkType="Protocol"&gt;NCT01852292&lt;/ulink&gt;; CBKM120H2201; BERIL-1) was planned to evaluate buparlisib plus &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; versus placebo plus paclitaxel in patients (expected n = 150) in Canada and Thailand with recurrent or metastatic head and neck cancer previously pre-treated with a platinum therapy. The primary endpoint was PFS at 4 weeks following treatment initiation. At that time, the trial was estimated to begin in August 2013 and complete in June 2015. In January 2014, recruitment began. In January 2015, the trial was also ongoing in the US, Australia, France, Germany, Hungary, India, Ireland, Italy, Japan, Korea, Poland, Russia, Spain, Switzerland, Taiwan and the UK and the trial was expected to complete in November 2015 [&lt;ulink linkID="1431818" linkType="Reference"&gt;1431818&lt;/ulink&gt;]. In June 2016, clinical data were presented at the 52nd ASCO meeting in Chicago, IL. The trial met its primary endpoint, demonstrating improved PFS for the combination of buparlisib plus paclitaxel vs placebo plus paclitaxel. The median PFS (primary endpoint) was 4.6 and 3.5 months in buparlisib and placebo groups, respectively, with hazard ratio of 0.65. Median overall survival (OS; key secondary endpoint) was 10.4 and 6.5 months in buparlisib and placebo groups, respectively, with hazard ratio of 0.72   [&lt;ulink linkID="1766385" linkType="Reference"&gt;1766385&lt;/ulink&gt;]. In August 2016, the trial was ongoing but no longer recruiting, and at that time the study was expected to complete in March 2017 [&lt;ulink linkID="1431818" linkType="Reference"&gt;1431818&lt;/ulink&gt;]. In January 2017, data were published. Data demonstrated that, there was improved clinical efficacy with a manageable safety profile, improvement was observed in progression free survival in buparlisib group (95% CI 3·5–5·3) compared to placebo group (hazard ratio 0·65 [95% CI 0·45–0·95], nominal one-sided p=0·011), the median progression free survival (PFS) was 4.6 and 3.5 months, respectively [&lt;ulink linkID="2058396" linkType="Reference"&gt;2058396&lt;/ulink&gt;], [&lt;ulink linkID="2058132" linkType="Reference"&gt;2058132&lt;/ulink&gt;]. In June 2018, data from biomarker analysis were published.  Data demonstrated that, patients with TP53 mutated gene (HR = 0.55), HPV-negative status (HR = 0.51) or low mutational load (HR = 0.57) improved overall 	survival  (OS) with the combination of buparlisib and paclitaxel  and also improved OS in patients with presence of intratumoral TILs ≥10% (HR = 0.51), stromal TILs ≥15% (HR = 0.53), intratumoral CD8-positive cells ≥5% (HR = 0.45), stromal CD8-positive cells ≥10% (HR = 0.47), or CD8-positive cells in invasive margins &amp;gt;25% (HR = 0.37) [&lt;ulink linkID="2058384" linkType="Reference"&gt;2058384&lt;/ulink&gt;], [&lt;ulink linkID="2058132" linkType="Reference"&gt;2058132&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2017, clinical data from a pivotal study (&lt;ulink linkID="117133" linkType="Protocol"&gt;NCT01816984&lt;/ulink&gt;) which evaluated the safety and efficacy of buparlisib in combination with cetuximab in patients with recurrent/metastatic head and neck cancer were presented at the 53rd ASCO meeting in Chicago, IL. Patients were given buparlisib (100 mg daily) starting day -7 and daily thereafter. Patients (n = 12) received escalating doses of buparlisib (dose level-1: 80 mg; dose level-2: 100 mg) followed by a dose expansion  (100 mg) in combination with cetuximab (500 mg/m2, q14d) until significant adverse events or progressive disease were observed. The MTD was 100 mg of buparlisib (qd) when given along with cetuximab. A total of ten patients were remained on study beyond the first radiographic examination time point and were evaluable for response (defined by RECIST v1.1); of these ten patients, partial response, stable disease and progressive disease were observed in one, four, and five patients, respectively. Median overall survival was 302.5 months (HPV+: 414 days and HPV- : 175 days). Toxicity was reported by 10 patients during treatment  [&lt;ulink linkID="1932423" linkType="Reference"&gt;1932423&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In June 2018, clinical data from phase I study (&lt;ulink linkID="182044" linkType="Protocol"&gt;NCT02113878&lt;/ulink&gt;) of the buparlisib  with concurrent chemoradiotherapy (CRT) in patients with high risk locally advanced squamous cell cancer of the head and neck were presented at the 54th ASCO Annual Meeting in Chicago, IL. Patients (n = 23) received buparlisib (40, 60, 80 and 100 mg, daily) during a 2-week run-in phase and during CRT consisting of 70Gy/35fx of radiotherapy plus weekly cisplatin (30, 35, 40 mg/m2). Among patients enrolled on dose level 1 (DL-1; n = 7) (buparlisib 40 mg daily, cisplatin 30 mg/m2 iv weekly/IMRT), a patient reported grade 4 rash, which resolved upon discontinuation of drug. Among six patients on DL-2 (buparlisib 40mg daily, cisplatin 35 mg/m2, iv  weekly/IMRT), four DLTs were reported (grade 3 neutropenia, LFT abnormalities, mucositis, and  rash). Grade 4 hyperamylasemia was reported by a patient. At DL-1 and -2, complete response was observed in four and one patient; partial response in six and two patients; stable response in two and two patients, respectively. Median PFS was 13.3 months (no stable estimate yet) and not reached at DL-1 and -2; 12-month proportion of progression-free was 94%. Median overall survival was not reached; 12-month OS was 93% (83% at DL-2). A death was reported at DL-2 [&lt;ulink linkID="2039633" linkType="Reference"&gt;2039633&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Cervical cancer &lt;/subtitle&gt;In June 2012, a non-randomized, open-label, single-group assignment, phase II trial (&lt;ulink linkID="88168" linkType="Protocol"&gt;NCT01613677&lt;/ulink&gt;; CBKM120ZBR01; MACS1809) was planned in patients (expected n = 27) in Brazil with recurrent unresectable or metastatic cervical cancer after palliative cisplatin-based regimen failure. The primary endpoint was severity and frequency of adverse events over 18 months. At that time, the trial was estimated to begin in January 2014 and complete in June 2015 [&lt;ulink linkID="1431819" linkType="Reference"&gt;1431819&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Non-Hodgkin's lymphoma&lt;/subtitle&gt;In September 2012, a phase II, non-randomized, open-label study (&lt;ulink linkID="92558" linkType="Protocol"&gt;NCT01693614&lt;/ulink&gt;; CBKM120Z2402; 2012-002208-41) was planned to commence in the US and EU, to evaluate the safety and efficacy of buparlisib (100 mg qd) in patients (estimated n = 66) with relapsed or refractory DLBCL, MCL or FL. The study began in February 2013 and was slated for completion in March 2015  [&lt;ulink linkID="1336715" linkType="Reference"&gt;1336715&lt;/ulink&gt;]. In December 2014, clinical data were presented at the 56th ASH Meeting in San Francisco, CA. Overall, complete response and partial responses  were  4 and 8%, respectively. Some decrease in tumor burden was reported in 31% of patients. The most common AEs of all grades were hyperglycemia and nausea (39% each), depression (31%), anxiety and fatigue (23% each), vomiting and diarrhea (19% each), and abdominal pain (15%). On-treatment deaths were seven [&lt;ulink linkID="1617715" linkType="Reference"&gt;1617715&lt;/ulink&gt;]. In December 2015, further clinical data from the trial were presented, at the 57th ASH Annual meeting and exposition in Orlando, FL. The overall response rate in DLBCL, MCL, and FL cohorts was 11.5, 22.7, and 25.0%. Complete response, partial response, stable disease, and progressive disease were regarded as best overall response by 3.8, 4.5, and 0; 7.7, 18.2 and 25; 19.2, 59.1, and 62.5; and 46.2, 9.1, and 4.2% of patients with DLBCL, MCL, and FL, respectively.  Overall, a reduction in investigator-assessed tumor size was observed in 35, 80 and 95.5% of patients. Median duration of responses was 2.2, not reached, and 11.0 months patients with DLBCL, MCL, and FL, respectively. Median PFS and OS were 1.8, 11.3, and 9.8 and 5.2 months, not reached and not reached in DLBCL, MCL and FL cohorts, respectively [&lt;ulink linkID="1718445" linkType="Reference"&gt;1718445&lt;/ulink&gt;]. In July 2016, the trial was ongoing but not recruiting, and at that time, the study was expected to complete in December 2016   [&lt;ulink linkID="1336715" linkType="Reference"&gt;1336715&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Chronic lymphocytic leukemia&lt;/subtitle&gt;In April 2015, a phase II study (&lt;ulink linkID="220598" linkType="Protocol"&gt;NCT02340780&lt;/ulink&gt;; I216) of buparlisib, led by &lt;ulink linkID="1120666" linkType="Company"&gt;Canadian Cancer Trials Group&lt;/ulink&gt;, was initiated in patients (expected n = 29) with relapsed and refractory chronic lymphocytic leukemia in Canada; at that time, the study was expected to be completed in January 2018 [&lt;ulink linkID="1686422" linkType="Reference"&gt;1686422&lt;/ulink&gt;]. In December 2017, data from Simon 2 stage were presented at 59th ASH Annual Meeting and Exposition in Atlanta, GA. In patients treated with buparlisib, partial response was observed in 6% of patients; stable disease was observed in 5% of patients; overall invaluable patients were 2; median duration of response was 14.4 months. In &amp;gt;/= 15% of patients treated with buparlisib, non-hematologic AEs including diarrhea, nausea, fatigue, anorexia, dysgeusia, headache, anxiety, dyspepsia, alopecia and rash was were reported by 5, 4, 4, 3, 3, 2, 2, 2, 2 and 2, respectively patients [&lt;ulink linkID="1988333" linkType="Reference"&gt;1988333&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Solid tumor&lt;/subtitle&gt;In June 2018, clinical data from phase I/Ib escalation/expansion studies (&lt;ulink linkID="259726" linkType="Protocol"&gt;NCT02756247&lt;/ulink&gt;) were performed to evaluate the safety and efficacy of ibrutinib in combination with buparlisib in patients relapsed/refractory diffuse large B cell lymphoma (DLBCL), mantle cell lymphoma (MCL) and follicular lymphoma (FL) patients were presented at the 54th ASCO Annual Meeting in Chicago, IL. Patients (n = 37) received po qd doses of ibrutinib (420 or 560 mg) and buparlisib (80 or 100 mg) on a 28-day cycle. Grade &amp;gt;/= 3 adverse events (AEs) were reported in 61%. Hyperglycemia, diarrhea, bilirubin elevation, thrombocytopenia, fatigue and ALT elevation were the most common reported AEs. In all, DLBCL, FL, and MCL patients, overall response rate was 51, 29, 20, and 76%; complete response was 43, 21, 20, and 71%; partial response was 8, 7, 0, and 6%; stable disease was 5, 0, 60, and 0%, respectively; progression of disease was 41, 71, 20, and 24%, respectively. Median time of response was 1.7 and 2.1 months, in MCL and DLBCL group, respectively [&lt;ulink linkID="2039237" linkType="Reference"&gt;2039237&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2018, clinical data from investigator-initiated, single-arm, open-label trial (&lt;ulink linkID="216964" linkType="Protocol"&gt;NCT02303041&lt;/ulink&gt;) were presented at 76th AAD Annual Meeting in San Diego, CA. Patients (n = 10) received &lt;ulink linkID="61926" linkType="Drug"&gt;sonidegib&lt;/ulink&gt; (200 mg/day) + buparlisib (80 mg/day). During the follow-up period, buparlisib dose was reduced to 40 mg first and then to 20 mg. The median progression free survival was found to be 13.8 months, in comparison with vismodegib in the ERIVANCE study (9.5 months) and the sonidegib 200 mg arm in the BOLT study (20 months). Partial response, stable disease and progressive disease were observed in one, four and two patients, respectively. The grade 3 toxicity might limit utility of the sonidegib/buparlisib combination in advanced basal cell carcinoma patients [&lt;ulink linkID="2006518" linkType="Reference"&gt;2006518&lt;/ulink&gt;].  &lt;/para&gt;&lt;para&gt;In June 2017, clinical data from a single center, phase I/IIb study (&lt;ulink linkID="259726" linkType="Protocol"&gt;NCT02756247&lt;/ulink&gt;)  were presented at the 53rd ASCO meeting in Chicago, IL. Patients (n = 16) received po daily doses of ibrutinib and buparlisib until treatment progression or maximum treatment duration of three years. Complete response and stable disease was observed in one and one patients (diffuse large B-cell lymphoma), seven and two patients (mantle cell lymphoma), three and three patients (follicular lymphoma). Combination of ibrutinib and buparlisib were well tolerated [&lt;ulink linkID="1932291" linkType="Reference"&gt;1932291&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In March 2013, a non-randomized, single-group assignment, open-label, phase II trial (&lt;ulink linkID="121820" linkType="Protocol"&gt;NCT01833169&lt;/ulink&gt;; CBKM120ZUS40) began in patients (expected n = 70) in the US with PI3K-activated tumors, including solid tumors and hematological malignancies. The primary endpoint was rate of clinical benefit over 16 weeks. At that time, the trial was estimated to complete in February 2017 [&lt;ulink linkID="1431816" linkType="Reference"&gt;1431816&lt;/ulink&gt;]. In January 2015,  clinical data from 18  colorectal cancer  patients   were presented at the 2015 ASCO Gastrointestinal Cancer Symposium in San Francisco, CA.​ At week 16, clinical benefit criteria were not met by 13 patients. Stable disease was seen in two patients at week 8. Nausea, fatigue, vomiting, diarrhea, anxiety and decreased appetite  were the frequently observed adverse events     [&lt;ulink linkID="1632678" linkType="Reference"&gt;1632678&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2014, clinical data were presented from a randomized, parallel phase I studies of two schedules for the treatment of advanced solid tumors at the 39th European Society for Medical Oncology congress in Madrid, Spain.  Tmax, Cmax and AUC 0 to 8 h values were estimated to be 4.83 hr, 284.83 ng/ml and 1219.59 hr.ng/ml, respectively for BKM-120 50 mg dose group; 3.67 hr, 576.00 ng/ml and 2547.13 hr.ng/ml, respectively for BKM-120 80 mg dose group and 1.71hr, 933.29 ng/ml and 3463.51 hr.ng/ml, respectively for BKM-120 100 mg dose group in group one (n = 16). Tmax, Cmax and AUC 0 to 8 h values were estimated to be 2.13 hr, 399.00 ng/ml and 1515.76 hr.ng/ml, respectively for BKM-120 50 mg dose group; 2.08 hr, 554.83 ng/ml and 1972.29 hr.ng/ml, respectively for BKM-120 80 mg dose group and 2.38 hr, 960.25 ng/ml and 3411.39 hr.ng/ml, respectively for BKM-120 100 mg dose group in group one (n = 14) [&lt;ulink linkID="1597507" linkType="Reference"&gt;1597507&lt;/ulink&gt;]. &lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;In September 2012, Novartis and &lt;ulink linkID="14190" linkType="Company"&gt;AstraZeneca&lt;/ulink&gt; were collaborating on an investigator-sponsored, non-randomized, single-group-assignment, phase I trial (&lt;ulink linkID="88528" linkType="Protocol"&gt;NCT01623349&lt;/ulink&gt;; 12-159) that was initiated in the US  to evaluate  &lt;ulink linkID="16063" linkType="Drug"&gt;olaparib&lt;/ulink&gt; in combination with either   buparlisib or &lt;ulink linkID="65353" linkType="Drug"&gt;alpelisib&lt;/ulink&gt; in patients (n = 118) with  recurrent TNBC  or high grade serous ovarian cancer. At that time, the trial was expected to complete in December 2014 [&lt;ulink linkID="2135429" linkType="Reference"&gt;2135429&lt;/ulink&gt;].   In May 2014, data from the multicenter, dose-escalation phase I trial of  olaparib along with buparlisib performed in 34 high-grade serous ovarian cancer or TNBC patients were presented at the 50th ASCO meeting in Chicago, IL. Clinical benefit was observed at all dose levels [&lt;ulink linkID="1559938" linkType="Reference"&gt;1559938&lt;/ulink&gt;].  In April 2017, clinical data were presented at the 108th AACR Annual Meeting in Washington DC. Patients (n = 46; 16 BC and 30 OC) received olaparib (tablet, biw) and alpelisib (daily) on 28-day cycle, both po. The MTD was 200 mg alpelisib (qd) and 200 mg olaparib (biw). Hyperglycemia, rash and fever with decreased neutrophil count were the DLT reported during the study period. The objective response rate (ORR) among patients with OC and received study drugs (with platinum resistant disease) was 36% by RECIST 1.1 (all partial responses (PR)) [&lt;ulink linkID="1914009" linkType="Reference"&gt;1914009&lt;/ulink&gt;]. In August 2018, the trial was expected to complete in December 2019 [&lt;ulink linkID="2135429" linkType="Reference"&gt;2135429&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2012, data from a phase Ib trial (&lt;ulink linkID="67911" linkType="Protocol"&gt;NCT01155453&lt;/ulink&gt;) of buparlisib plus &lt;ulink linkID="55288" linkType="Drug"&gt;trametinib DMSO&lt;/ulink&gt; were presented at the 48th ASCO meeting in Chicago, IL. The recommended phase II dose was 70 mg of buparlisib with 1.5 mg of trametinib DMSO. At the time data were reported, dose expansion was ongoing in patients with RAS- or BRAF-mutant pancreatic, ovarian  or NSCLC [&lt;ulink linkID="1296533" linkType="Reference"&gt;1296533&lt;/ulink&gt;]. In September 2013,  data  from the  dose-escalation study were presented at the 2013 European Cancer Congress in Amsterdam, The Netherlands.  The  recommended phase II dose was 60 mg BKM-120 + 1.5 mg GSK-1120212  . A total of 19 of 21 KRAS-/BRAF-mutant ovarian cancer patients were evaluable for response. Best overall response (BOR) of partial response was observed in seven patients and stable disease (SD) was observed in nine patients. Of 24 pancreatic patients, 19 were evaluable for efficacy. A total 12 of 19 patients achieved BOR of SD. Overall, 7 of 11 evaluable NSCLC patients (n = 17) had BOR of SD [&lt;ulink linkID="1480284" linkType="Reference"&gt;1480284&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2011, Novartis had initiated a phase Ib study evaluating &lt;ulink linkID="55305" linkType="Drug"&gt;MEK-162&lt;/ulink&gt; and buparlisib in patients with advanced solid tumors [&lt;ulink linkID="1213604" linkType="Reference"&gt;1213604&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In January 2011, a phase Ib, multicenter, open-label, four-arm, dose-escalation study (&lt;ulink linkID="74258" linkType="Protocol"&gt;NCT01285466&lt;/ulink&gt;; CBEZ235A2118) of oral &lt;ulink linkID="57048" linkType="Drug"&gt;BEZ-235&lt;/ulink&gt; and buparlisib in combination with weekly &lt;ulink linkID="3803" linkType="Drug"&gt;paclitaxel&lt;/ulink&gt; in patients (expected n = 72) with advanced solid tumors and weekly paclitaxel/&lt;ulink linkID="6386" linkType="Drug"&gt;trastuzumab&lt;/ulink&gt; in patients with HER2+ metastatic breast cancer. At that time, the study was expected to complete by November 2013 [&lt;ulink linkID="1331381" linkType="Reference"&gt;1331381&lt;/ulink&gt;]. In October 2012, preliminary data from 74 patients in arm 1 (&lt;ulink linkID="57048" linkType="Drug"&gt;BEZ-235&lt;/ulink&gt; + paclitaxel) and arm 2 (buparlisib + paclitaxel) were presented at the 37th European Society for Medical Oncology Congress in Vienna, Austria. The MTD  (primary objective) of the combinations were  800 mg/day BEZ-235 plus 80 mg/m2 paclitaxel (arm 1)  and 100 mg/day buparlisib and 80 mg/m2 paclitaxel (arm 2).  PR was shown by 1 and 2 patients in arms 1 and 2, respectively, and 1 patient in arm 2 showed complete response.  At that time, arms 3 and 4 of this study evaluating the MTD of BEZ-235/buparlisib plus paclitaxel and transtuzumab  metastatic/locally advanced HER2-overexpressing breast cancer patients were ongoing  [&lt;ulink linkID="1324993" linkType="Reference"&gt;1324993&lt;/ulink&gt;]. In June 2014, further data were presented at the 50th ASCO meeting in Chicago, IL. A phase Ib trial  with buparlisib (BEZ235) in combination with paclitaxel in patients (n = 64) with in advanced solid tumors or buparlisib along with paclitaxel plus trastuzumab in HER+ breast cancer patients. Progressive response and stable disease were reported by 7 and 27 patients with an overall response rate (ORR) of 17% in arm-2 and 3 and 5 patients with an ORR of 27% in arm-2, respectively [&lt;ulink linkID="1562402" linkType="Reference"&gt;1562402&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;By September 2009, patient recruitment for a multicenter, open-label, dose-escalation, phase Ia study of orally administered buparlisib in patients with advanced solid malignancies had begun in the US [&lt;ulink linkID="1049675" linkType="Reference"&gt;1049675&lt;/ulink&gt;]. In December 2009, Novartis disclosed results from the trial where buparlisib was administered at 100 mg/day. A total of 2 patients had clinical partial responses and 8 out of 11 had metabolic partial responses.  The longest time that the patients stayed on the study  was 12 months (colon cancer). The MTD had been defined as 100 mg/day [&lt;ulink linkID="1065920" linkType="Reference"&gt;1065920&lt;/ulink&gt;]. In April 2010, these data were presented at the 101st AACR meeting in Washington DC [&lt;ulink linkID="1088681" linkType="Reference"&gt;1088681&lt;/ulink&gt;], [&lt;ulink linkID="1093703" linkType="Reference"&gt;1093703&lt;/ulink&gt;]. In June 2011, further data   were presented at the 47th ASCO meeting in Chicago, IL. Partial response was observed in one confirmed and two unconfirmed patients on buparlisib therapy. A total of 28 patients had stable disease; 20 patients experienced prolonged stable disease (&amp;gt; 16 weeks) on treatment. Buparlisib inhibited tumor metabolic activity as early as cycle 1. At that time, sub-analysis in patients with activated PI3K pathway was ongoing [&lt;ulink linkID="1195481" linkType="Reference"&gt;1195481&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2015, clinical data were presented from a  phase I study in 35 patients at the 106th AACR meeting in Philadelphia, PA. Patients received &lt;ulink linkID="13340" linkType="Drug"&gt;everolimus&lt;/ulink&gt; (5 or 10 mg, qd) and buparlisib (120, 40, 60 and 80 mg, qd) continuously. Overall, progressive disease and stable disease  were reported in 32 and 17% of patients, respectively. The combination of everolimus plus buparlisib was safe and well tolerated without any significant drug-drug interaction [&lt;ulink linkID="1648939" linkType="Reference"&gt;1648939&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2014, a non-randomized, open-label, parallel-assigned, single-dose, multicenter phase I trial (&lt;ulink linkID="170417" linkType="Protocol"&gt;NCT02048787&lt;/ulink&gt;; CBKM120C2113, 2013-003384-64) was planned to be initiated in moderate to severe renal impaired patients (expected n = 24) in Bulgaria, Czech Republic, Germany and Romania to evaluate the   safety and pharmacokinetics of buparlisib. At that time, the trial was expected to complete in December 2014; in March 2014, the trial was initiated in Bulgaria [&lt;ulink linkID="1533497" linkType="Reference"&gt;1533497&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2012, data from three patients from a phase I (&lt;ulink linkID="64184" linkType="Protocol"&gt;NCT01068483&lt;/ulink&gt;; CBKM120X2101) and  a phase II study (&lt;ulink linkID="74799" linkType="Protocol"&gt;NCT01297491&lt;/ulink&gt;; CBKM120D2201) evaluating the effect of buparlisib on brain metastasis were presented  at the 37th European Society for Medical Oncology Congress in Vienna, Austria. Of the three patients (treated with 100 mg/day dose) evaluable, two showed partial responses with one metastatic breast cancer patient having 28% reduction in brain lesion and one NSCLC patient showing complete disappearance of non-targeted brain lesion.   No radiological evidence of disease progression in the brain was reported in these three patients [&lt;ulink linkID="1324986" linkType="Reference"&gt;1324986&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2012, data from a dose-escalation phase I study (&lt;ulink linkID="64184" linkType="Protocol"&gt;NCT01068483&lt;/ulink&gt;; CBKM120X2101) of buparlisib  in advanced solid tumor patients (n = 83) were presented  at the 37th European Society for Medical Oncology Congress in Vienna, Austria.  The mean plasma C-peptide concentrations were increased following the first buparlisib dose on day 1 of cycle 1 in 72 patients evaluable. Reduction in  Ki-67 were also observed in six of the ten tumor tissues analyzed, suggesting a possible effect on cell proliferation; four of these six patients showed partial response (PR) or stable disease (SD), and greater Ki-67 decreases were seen in patients who showed PR. In 51 patients analyzed, pS6 inhibition in skin increased moderately with buparlisib, suggesting dose-related inhibition of PI3K pathway [&lt;ulink linkID="1324996" linkType="Reference"&gt;1324996&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2009, phase I, open-label study (&lt;ulink linkID="74050" linkType="Protocol"&gt;NCT01283503&lt;/ulink&gt;) was initiated in Japan to access the safety, tolerability and MTD of buparlisib in Japanese patients (expected n = 30) with advance solid tumors [&lt;ulink linkID="1247186" linkType="Reference"&gt;1247186&lt;/ulink&gt;]. In November 2011, clinical data were presented at the 3rd AACR-NCI-EORTC International Conference in San Francisco, CA. Patients (n = 15) received buparlisib (25, 50 and 100 mg/day po, qd). buparlisib up to 100 mg was generally well tolerated. Buparlisib 100 mg/day was determined as the recommended dose in the Japanese patients. Buparlisib showed rapid absorption with Cmax achieved 1 to 3 h post-dose.  The Cmax and AUC(0 to 24) values of buparlisib was found to be increased dose-proportionally from 25 to 100 mg/day. The disease control rate with buparlisib was 40%. A total of six patients, including one with unconfirmed PR had stable disease with duration ranging from 55 to 116 days. A patient with head and neck cancer and metastasis of neck lymph node treated with buparlisib (100 mg/day) completed cycle-1 without any DLT; in cycle-4 an unconfirmed PR response was achieved by this patient with remarkable tumor shrinkage of 76.3% [&lt;ulink linkID="1240108" linkType="Reference"&gt;1240108&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;&lt;subtitle&gt;Miscellaneous studies&lt;/subtitle&gt;In June 2017, clinical data from a phase II study (&lt;ulink linkID="154869" linkType="Protocol"&gt;UMIN000011217&lt;/ulink&gt;) were presented from 42 patients at the 53rd ASCO meeting in Chicago, IL. Patients were treated with BKM-120 100 mg/day (po) in a 28-day cycle. Disease progression (78.6%), adverse events (AEs; 9.5%), patients refusal (7.1%), and other (4.8%) were the reasons for treatment discontinuations. Median progression-free survival and overall survival was 2.3 and 9 months, respectively. Complete response, partial response, stable disease and progressive disease were achieved by 0, 2.4, 48.8 and 48.8% of patients, respectively. Disease control rate and response rate were 51.2 and 2.4%, respectively. Hyperglycemia, rash maculopapular, anorexia, increased ALT and AST, mucositis oral, nausea, diarrhea, C-peptide increased, malaise, anxiety, dry skin, fatigue, vomiting, depression, platelet count decreased and dysgeusia were the major AEs reported in &amp;gt;10% of patients [&lt;ulink linkID="1931870" linkType="Reference"&gt;1931870&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In  October 2016, clinical data from a phase II study (&lt;ulink linkID="216743" linkType="Protocol"&gt;NCT02301364&lt;/ulink&gt;) which evaluated the efficacy and safety of buparlisib, in patients (n = 4) with recurrent/refractory primary and secondary CNS lymphoma were presented at the ESMO 2016 Congress in Copenhagen, Denmark. All patients received buparlisib (100 mg qd). The overall response rate was 25% with a partial response; and this patient developed psychiatric symptoms within 8 weeks of treatment that resulted in drug discontinuation. Overall, buparlisib had acceptable toxicities in patients with CNS lymphoma; and the trial was closed prematurely due to limited clinical response [&lt;ulink linkID="1805910" linkType="Reference"&gt;1805910&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In September 2014, an investigator-led, open-label, phase II study (&lt;ulink linkID="208630" linkType="Protocol"&gt;NCT02220855&lt;/ulink&gt;; IUCRO-0478) was initiated in the US in patients (n = 27) with thymoma.  The trial was expected to complete in November 2017. In April 2016, recruitment was ongoing [&lt;ulink linkID="1605994" linkType="Reference"&gt;1605994&lt;/ulink&gt;]. In June 2018, further data were presented at 54th ASCO Annual Meeting in Chicago, IL. Partial response achieved by one patient with a median follow up of 16.6 m and that lasted till 9.7 months. In patients treated with buparlisib, the most common grade 3-4 adverse events including dyspnea, rash, pneumonitis, anxiety, fatigue and hyperglycemia were reported by 21, 14, 7, 7, 7 and 7%, respectively [&lt;ulink linkID="2039210" linkType="Reference"&gt;2039210&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In June 2014, clinical data were presented at the 50th ASCO meeting in Chicago, IL. Out of 19 patients, 14 patients showed inactivation of pRS6. Level of phosphorylated Akt was decreased in 4 out of 11 tumors [&lt;ulink linkID="1562801" linkType="Reference"&gt;1562801&lt;/ulink&gt;]&lt;/para&gt;&lt;para&gt;In September 2013,  data were presented from four phase I and II studies (X2101, X1101, C2201 and D2201) in 198 patients at the 2013 European Cancer Congress in Amsterdam, the Netherlands. Across the four studies, the maximum change in plasma C-peptide levels at equivalent doses was similar and clear/consistent correlations were not observed between fasting plasma glucose levels or C-peptide and tumor shrinkage [&lt;ulink linkID="1481431" linkType="Reference"&gt;1481431&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In October 2011, an open-label, non-randomized, single-group assignment, phase I trial (&lt;ulink linkID="98228" linkType="Protocol"&gt;NCT01727128&lt;/ulink&gt;; CBKM120C2104; 2011-002311-28) began in patients (expected n = 36) in Europe and South Africa with mild, moderate and severe hepatic impairment. The primary endpoint was the pharmacokinetics of buparlisib. At that time, the trial was estimated to complete in July 2013 [&lt;ulink linkID="1431817" linkType="Reference"&gt;1431817&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;In March 2019, preclinical data were presented at the 7th International Conference on Innovative Approaches in Head &amp;amp; Neck Oncology (ICHNO) in Barcelona, Spain. Data demonstrated that buparlisib inhibited tumor growth, and showed a dose response trend in anti-PD1 refractory tumor bearing mice and dose range was consistent with previous preclinical studies conducted by Novartis [&lt;ulink linkID="2130065" linkType="Reference"&gt;2130065&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In December 2015, preclinical data were presented at the 57th ASH Annual Meeting and Exposition in Orlando, FL. Increased survival from 21 to 28 days was observed in BaF3VF-luc injected mice treated with BKM-120 (60 mpk). A strong synergism against BaF3-EpoR-VF cells was observed with the triple combinations of BKM-120 and ruxolitinib + everolimus or PP-242. Triple combination of low doses (30 nM each) reduced colony formation from bone marrow cells of JAK2VF knock-in (KI) mice compared with WT mice (-93.7 versus -44.7%). Triple combination treatment of KI mice with low doses of BKM-120 (30 mpk) + ruxolitinib (30 mpk) + everolimus (1.5 mpk) resulted in reduction of leukocytosis and reticulocyte count in vivo. The levels of p-4eBP1 and p-STAT5 in the spleen were reduced in mice receiving combined versus single agent treatment [&lt;ulink linkID="1718993" linkType="Reference"&gt;1718993&lt;/ulink&gt;].In April 2015, preclinical data were presented at the 106th AACR meeting in Philadelphia, PA.  In EML4-ALK-translocated lung cancer cell line H2228, &lt;ulink linkID="69858" linkType="Drug"&gt;ceritinib&lt;/ulink&gt; in combination with buparlisib or alpelisib showed synergistic antiproliferative activity.  In human-mouse primary xenograft lung cancer model, ceritinib (25 mg/kg qd) plus buparlisib (35 mg/kg qd) treatment was significantly improved tumor growth delay when compared with ceritinib (50 mg/kg qd) treatment [&lt;ulink linkID="1648903" linkType="Reference"&gt;1648903&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;br&gt;&lt;/br&gt;In December 2013, preclinical data were presented at the 36th Annual CTRC-AACR San Antonio Breast Cancer Symposium, in San Antonio, TX. In everolimus-resistant xenografts, tumor regression occurred with BMK-120 as a single agent or in combination with fulvestrant [&lt;ulink linkID="1512922" linkType="Reference"&gt;1512922&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In December 2013, preclinical data were presented at the 55th ASH Meeting in New Orleans, LA. BMK-120 inhibited BAF3 VF, BaF3-EPoR VF, HEL and SET2 cells with the mean IC50 values ranging from 364 to 2000 nM. Proliferation of SET2 and BaF3-EpoR VF cells were synergistically inhibited by BMK-120 plus ruxolitinib. In BaF3 VF luc mouse model, the lifespan was increased from 21 to 27.2 and 28 days with BMK-120 at doses 45 and 60 mg/kg, respectively [&lt;ulink linkID="1503058" linkType="Reference"&gt;1503058&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In November 2012, preclinical data were published showing that buparlisib delayed tumor doubling from 5 to 26 days in a mouse model of triple negative breast cancer. Buparlisib in combination with &lt;ulink linkID="16063" linkType="Drug"&gt;olaparib&lt;/ulink&gt; delayed tumor doubling to more than 70 days and 50 days in the mouse model and xenotransplants from human tumors, respectively [&lt;ulink linkID="1339957" linkType="Reference"&gt;1339957&lt;/ulink&gt;], [&lt;ulink linkID="1340190" linkType="Reference"&gt;1340190&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In September 2012,  data were presented at the 37th European Society for Medical Oncology Congress in Vienna, Austria. In NIH-FOXn1rnu rats, buparlisib (5 mg/kg) prevented insulin-induced AKT phosphorylation in the brain, whereas, untreated insulin administered rats had substantial increase in the brain pAKT levels. The pAKT reduction correlated somewhat with the buparlisib levels. In HER2+ metastatic breast cancer xenograft mice, buparlisib (50 mg/kg) reduced the frequency of brain metastases significantly [&lt;ulink linkID="1324986" linkType="Reference"&gt;1324986&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In April 2012, preclinical data were presented at the 103rd AACR annual meeting in Chicago, IL. In vitro, combination treatment with buparlisib and &lt;ulink linkID="11460" linkType="Drug"&gt;imatinib&lt;/ulink&gt; resulted in synergistic or excess inhibition in both sensistive and resistant GIST cell lines.  In vivo, the combination of imatinib (100 mg/kg po, bid) and  buparlisib (30 mg/kg po, qd) demonstrated more potent growth suppression compared to either agent alone in an imatinib-resistant xenograft model [&lt;ulink linkID="1276342" linkType="Reference"&gt;1276342&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2011, preclinical data were presented at the 102nd AACR meeting in Orlando, FL. At high doses, the drug clustered with cytotoxic agents but not with other PI3K inhibitors in a panel of cancer cell lines. Buparlisib (1, 5 microM for 24 h) was found to cause a mitotic gene expression signature and also arrested prometaphase in PI3K inhibitor-insensitive cells. At 5 microM, the drug  inhibited tubulin polymerization in interphase cells and in vitro assays. At doses of at least 50 mg/kg, buparlisib transiently increased phosphorylation of histone H3 [&lt;ulink linkID="1177145" linkType="Reference"&gt;1177145&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By July 2010, a series of buparlisib analogs had been synthesized. The most potent compound exhibited IC50 values of 0.017, 0.24 and 0.006 microM for PI3Kalpha, beta and delta respectively [&lt;ulink linkID="1161750" linkType="Reference"&gt;1161750&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In April 2010, preclinical data were presented at the 101st AACR meeting in Washington DC. Buparlisib was highly active against class IA and class IB PI3Ks. It dose-dependently induced apoptosis in a number of cell lines and showed antiproliferative activity, most notably in PIK3CA. Additionally, the compound showed favorable pharmacokinetic data both iv and po in mouse models. In female athymic mice bearing subcutaneous U87MG tumors, tumor volume was reduced with po buparlisib treatment. Similar tumor volume reduction to &lt;ulink linkID="6386" linkType="Drug"&gt;trastuzumab&lt;/ulink&gt; in  mouse breast cancer models were seen with buparlisib as monotherapy, and when the drugs were administered in combination; synergistic tumor volume reduction was also seen when buparlisib was administered in combination with &lt;ulink linkID="28972" linkType="Drug"&gt;selumetinib&lt;/ulink&gt;. Buparlisib showed phospho-Akt down-modulation in a concentration-dependent manner and achieved maximum tumor-growth inhibition when dosed at 60 mg/kg in mouse xenograft efficacy studies   [&lt;ulink linkID="1088964" linkType="Reference"&gt;1088964&lt;/ulink&gt;], [&lt;ulink linkID="1088963" linkType="Reference"&gt;1088963&lt;/ulink&gt;] [&lt;ulink linkID="1092243" linkType="Reference"&gt;1092243&lt;/ulink&gt;], [&lt;ulink linkID="1088664" linkType="Reference"&gt;1088664&lt;/ulink&gt;], [&lt;ulink linkID="1093703" linkType="Reference"&gt;1093703&lt;/ulink&gt;], [&lt;ulink linkID="1088681" linkType="Reference"&gt;1088681&lt;/ulink&gt;]. Further data presented at the meeting demonstrate buparlisib to significantly decrease tumor microvascular Ieakage in the BN472 orthotopic breast cancer model [&lt;ulink linkID="1089508" linkType="Reference"&gt;1089508&lt;/ulink&gt;]. Similar data were presented at the 240th ACS meeting in Boston, MA in August 2010 [&lt;ulink linkID="1123597" linkType="Reference"&gt;1123597&lt;/ulink&gt;].&lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In August 2016, the EMA's Pediatric Committee adopted positive opinion on a product-specific waiver for buparlisib in the treatment of metastatic head and neck squamous cell carcinoma [&lt;ulink linkID="1793043" linkType="Reference"&gt;1793043&lt;/ulink&gt;].&lt;br&gt;&lt;/br&gt;&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="307">Squamous cell carcinoma</Indication><StatusDate>2019-03-15T00:00:00.000Z</StatusDate><Source id="2130065" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2019-03-15T00:00:00.000Z</StatusDate><Source id="2130065" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1744">Mantle cell lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1744">Mantle cell lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1744">Mantle cell lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2016-06-06T00:00:00.000Z</StatusDate><Source id="1786218" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="725">Solid tumor</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2016-06-06T00:00:00.000Z</StatusDate><Source id="1786218" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2016-06-06T00:00:00.000Z</StatusDate><Source id="1786218" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="427">Uterine cervix tumor</Indication><StatusDate>2016-03-29T00:00:00.000Z</StatusDate><Source id="1431819" type="TRIALREG"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="IN">India</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2454">Glioblastoma</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2016-06-06T00:00:00.000Z</StatusDate><Source id="1786218" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="XH">Far East</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2016-06-06T00:00:00.000Z</StatusDate><Source id="1786218" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2454">Glioblastoma</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2016-06-06T00:00:00.000Z</StatusDate><Source id="1786218" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2454">Glioblastoma</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="2454">Glioblastoma</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2016-06-06T00:00:00.000Z</StatusDate><Source id="1786218" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="1">Adverse Events</DiscontinuedReason><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2016-06-06T00:00:00.000Z</StatusDate><Source id="1786218" type="OTHER"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="LB">Lebanon</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2017-01-25T00:00:00.000Z</StatusDate><Source id="1896505" type="CORPORATE"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2016-01-27T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="IL">Israel</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1744">Mantle cell lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1744">Mantle cell lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1744">Mantle cell lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate>2011-11-08T00:00:00.000Z</StatusDate><Source id="1240245" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="XD">North America</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate>2011-11-08T00:00:00.000Z</StatusDate><Source id="1240245" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate>2012-01-18T00:00:00.000Z</StatusDate><Source id="1277046" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2010-05-07T00:00:00.000Z</StatusDate><Source id="1230847" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="ES">Spain</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2010-05-07T00:00:00.000Z</StatusDate><Source id="1230847" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2010-04-20T00:00:00.000Z</StatusDate><Source id="1088964" type="OTHER"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2012-06-20T00:00:00.000Z</StatusDate><Source id="1385489" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TW">Taiwan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2014-05-08T00:00:00.000Z</StatusDate><Source id="1534068" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1744">Mantle cell lymphoma</Indication><StatusDate>2012-09-04T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2012-09-04T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2012-09-04T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1744">Mantle cell lymphoma</Indication><StatusDate>2012-09-04T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2012-09-04T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2012-09-04T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1744">Mantle cell lymphoma</Indication><StatusDate>2012-09-04T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2012-09-04T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2012-09-04T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2012-09-04T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="319">Non-Hodgkin lymphoma</Indication><StatusDate>2012-09-04T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="BR">Brazil</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="427">Uterine cervix tumor</Indication><StatusDate>2012-06-05T00:00:00.000Z</StatusDate><Source id="1431819" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2011-02-22T00:00:00.000Z</StatusDate><Source id="1177993" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2011-02-22T00:00:00.000Z</StatusDate><Source id="1177993" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1705">Endometrioid carcinoma</Indication><StatusDate>2011-02-22T00:00:00.000Z</StatusDate><Source id="1177993" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2011-06-27T00:00:00.000Z</StatusDate><Source id="1200765" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2011-06-27T00:00:00.000Z</StatusDate><Source id="1200765" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2011-06-27T00:00:00.000Z</StatusDate><Source id="1200765" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2011-06-27T00:00:00.000Z</StatusDate><Source id="1200765" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TR">Turkey</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2013-06-02T00:00:00.000Z</StatusDate><Source id="1431815" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2013-06-02T00:00:00.000Z</StatusDate><Source id="1431815" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2011-06-27T00:00:00.000Z</StatusDate><Source id="1200765" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3257">Stage IV melanoma</Indication><StatusDate>2012-06-14T00:00:00.000Z</StatusDate><Source id="1277046" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2013-02-05T00:00:00.000Z</StatusDate><Source id="1383895" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2013-02-05T00:00:00.000Z</StatusDate><Source id="1383895" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2013-02-05T00:00:00.000Z</StatusDate><Source id="1383895" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="IL">Israel</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2013-02-05T00:00:00.000Z</StatusDate><Source id="1383895" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="ZA">South Africa</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-08T00:00:00.000Z</StatusDate><Source id="1336730" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-08T00:00:00.000Z</StatusDate><Source id="1336730" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-08T00:00:00.000Z</StatusDate><Source id="1336730" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2012-10-29T00:00:00.000Z</StatusDate><Source id="1338859" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-08T00:00:00.000Z</StatusDate><Source id="1336730" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="XE">South America</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-08T00:00:00.000Z</StatusDate><Source id="1336730" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2013-12-23T00:00:00.000Z</StatusDate></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2015-01-08T00:00:00.000Z</StatusDate><Source id="1336730" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2012-08-13T00:00:00.000Z</StatusDate><Source id="1336730" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2012-08-13T00:00:00.000Z</StatusDate><Source id="1336730" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2012-08-13T00:00:00.000Z</StatusDate><Source id="1336730" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CN">China</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="3665">Metastatic non small cell lung cancer</Indication><StatusDate>2012-03-30T00:00:00.000Z</StatusDate><Source id="1200765" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2009-10-31T00:00:00.000Z</StatusDate><Source id="1247186" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate>2012-04-30T00:00:00.000Z</StatusDate><Source id="1240245" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate>2012-04-30T00:00:00.000Z</StatusDate><Source id="1240245" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate>2012-04-30T00:00:00.000Z</StatusDate><Source id="1240245" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2013-04-23T00:00:00.000Z</StatusDate><Source id="1312374" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2013-04-23T00:00:00.000Z</StatusDate><Source id="1312374" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3246">Hormone refractory prostate cancer</Indication><StatusDate>2012-09-30T00:00:00.000Z</StatusDate><Source id="1312374" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="3205">Gastrointestinal stromal tumor</Indication><StatusDate>2012-04-30T00:00:00.000Z</StatusDate><Source id="1240245" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2015-01-09T00:00:00.000Z</StatusDate><Source id="1431818" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="XH">Far East</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2015-01-09T00:00:00.000Z</StatusDate><Source id="1431818" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="JP">Japan</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2015-01-09T00:00:00.000Z</StatusDate><Source id="1431818" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="IN">India</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2015-01-09T00:00:00.000Z</StatusDate><Source id="1431818" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2014-01-09T00:00:00.000Z</StatusDate><Source id="1431818" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate>2014-01-10T00:00:00.000Z</StatusDate><Source id="1439804" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2015-01-09T00:00:00.000Z</StatusDate><Source id="1431818" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate>2014-01-10T00:00:00.000Z</StatusDate><Source id="1439804" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="TH">Thailand</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2014-01-09T00:00:00.000Z</StatusDate><Source id="1431818" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CA">Canada</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate>2011-12-30T00:00:00.000Z</StatusDate><Source id="1331781" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2454">Glioblastoma</Indication><StatusDate>2011-12-30T00:00:00.000Z</StatusDate><Source id="1331781" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2015-03-05T00:00:00.000Z</StatusDate><Source id="1383895" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="IL">Israel</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2015-03-05T00:00:00.000Z</StatusDate><Source id="1383895" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="SG">Singapore</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2015-03-05T00:00:00.000Z</StatusDate><Source id="1383895" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2013-03-14T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2013-03-14T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="X5">Europe</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1744">Mantle cell lymphoma</Indication><StatusDate>2013-03-14T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2013-03-14T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1744">Mantle cell lymphoma</Indication><StatusDate>2013-03-14T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2013-03-14T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1745">Follicle center lymphoma</Indication><StatusDate>2013-03-14T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1744">Mantle cell lymphoma</Indication><StatusDate>2013-03-14T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="1749">Diffuse large B-cell lymphoma</Indication><StatusDate>2013-03-14T00:00:00.000Z</StatusDate><Source id="1336715" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="DE">Germany</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2012-12-31T00:00:00.000Z</StatusDate><Source id="1383895" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="AU">Australia</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="2436">Myelofibrosis</Indication><StatusDate>2015-03-05T00:00:00.000Z</StatusDate><Source id="1383895" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="2054">Hematological neoplasm</Indication><StatusDate>2013-03-31T00:00:00.000Z</StatusDate><Source id="1431816" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1111343">Adlai Nortye Pharmaceutical Co Ltd</Company><Country id="CN">China</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3673">Metastatic head and neck cancer</Indication><StatusDate>2018-07-10T00:00:00.000Z</StatusDate><Source id="2052696" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2014-03-11T00:00:00.000Z</StatusDate><Source id="2154987" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="LB">Lebanon</Country><DevelopmentStatus id="C2" sortOrder="11">Phase 2 Clinical</DevelopmentStatus><Indication id="3657">Metastatic breast cancer</Indication><StatusDate>2014-03-11T00:00:00.000Z</StatusDate><Source id="2154987" type="TRIALREG"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="CH">Switzerland</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2008-11-19T00:00:00.000Z</StatusDate><Source id="965240" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="23137">Novartis AG</Company><Country id="US">US</Country><DevelopmentStatus id="C1" sortOrder="10">Phase 1 Clinical</DevelopmentStatus><Indication id="725">Solid tumor</Indication><StatusDate>2009-09-22T00:00:00.000Z</StatusDate><Source id="1049575" type="CORPORATE"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><RegulatoryDesignationStatus><Row><RegulatoryDesignation id="2">Fast Track</RegulatoryDesignation><OwnerCompany id="1111343">Adlai Nortye Pharmaceutical Co Ltd</OwnerCompany><Country id="US">US</Country><Indication id="3673">Metastatic head and neck cancer</Indication><AwardedIndication>Treatment of head and neck squamous cell carcinoma</AwardedIndication><DesignationType id="1">Treatment</DesignationType><DesignationApplicationStatus id="1">Granted</DesignationApplicationStatus><MileStoneDate>2018-07-10T00:00:00.000Z</MileStoneDate></Row></RegulatoryDesignationStatus><Targets><Target id="PTGT-01553"><Name>Phosphoinositide 3-kinase</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Development Status Updated</Reason><Description>One or more development status entries have been updated</Description></ReasonForUpdate><ReasonForUpdate><Reason>Reference Added</Reason><Description>1 reference added [&lt;ulink url="utility.reference?i_reference_id=2154987" linkType="reference" linkID="2154987"&gt;2154987&lt;/ulink&gt;]							</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1029947">Sinopep Pharmaceutical Inc</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="23137">Novartis AG</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>c1c(c(cnc1N)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F</Smiles><Smiles>COc1ccc(cn1)Nc2cc(nc(n2)N3CCOCC3)c4cccc(c4)O</Smiles><Smiles>c1c(c(cnc1N)c2cc(nc(n2)N3CCOCC3)N4CCOCC4)C(F)(F)F.Cl</Smiles></StructureSmiles><Deals><Deal id="248313" title="Adlai Nortye Biopharma to develop and commercialize Novartis' buparlisib against cancer worldwide "/></Deals><PatentFamilies><PatentFamily id="1191770" number="WO-2010130779" title="Combination of a phosphoinositide 3-kinase inhibitor and an antidiabetic compound"/><PatentFamily id="1233561" number="WO-2010049481" title="Combination of a phosphatidylinositol-3-kinase (PI3k) inhibitor and a mTOR inhibitor"/><PatentFamily id="1703648" number="WO-2012065021" title="Dexamethasone combination therapy"/><PatentFamily id="2047124" number="WO-2010037715" title="Smoothened antagonism for the treatment of hedgehog pathway-related disorders"/><PatentFamily id="2295772" number="WO-2012044727" title="Manufacturing process for pyrimidine derivatives"/><PatentFamily id="2447373" number="WO-2013006532" title="Combination therapy comprising a CDK4/6 inhibitor and a PI3K inhibitor for use in the treatment of cancer"/><PatentFamily id="2486207" number="WO-2013030368" title="PI3k inhibitor for use in the treatment of bone cancer or for preventing metastatic dissemination of primary cancer cells into the bone"/><PatentFamily id="2519685" number="WO-2013063000" title="Method of treating gastrointestinal stromal tumors"/><PatentFamily id="2636392" number="WO-2013173283" title="Dosage regimen for a PI-3 kinase inhibitor"/><PatentFamily id="2650437" number="WO-2013184621" title="Combination of a 17-alpha-hydroxylase (C17,20-lyase) inhibitor and a specific PI3K inhibitor for treating a tumor disease"/><PatentFamily id="2664321" number="WO-2014006115" title="Combination of a phosphoinositide 3-kinase inhibitor and an inhibitor of the IL-8/CXCR interaction"/><PatentFamily id="2682957" number="WO-2014028566" title="Combination of PI3K inhibitor and c-Met inhibitor"/><PatentFamily id="2726119" number="WO-2014064058" title="Improved process for manufacturing 5-(2,6-di-4-morpholinyl-4-pyrimidinyl)-4-(trifluoromethyl)pyridin-2-amine"/><PatentFamily id="2771635" number="WO-2014113260" title="Androgen receptor modulator and uses thereof"/><PatentFamily id="2796445" number="WO-2014136048" title="Formulations of organic compounds"/><PatentFamily id="2805315" number="WO-2014147573" title="Combination therapy"/><PatentFamily id="2826695" number="WO-2014181252" title="Combination of a PI3K kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck"/><PatentFamily id="2846619" number="WO-2014199294" title="Pharmaceutical combinations of a PI3K inhibitor and a microtubule destabilizing agent"/><PatentFamily id="2851607" number="WO-2014203152" title="Pharmaceutical combinations"/><PatentFamily id="2896563" number="US-09439909" title="Compositions and methods for sensitizing a neoplastic cell to radiation"/><PatentFamily id="2976175" number="WO-2015107461" title="Pharmaceutical combinations"/><PatentFamily id="3063345" number="WO-2015168599" title="Combination therapies targeting mitochondria for cancer therapy"/><PatentFamily id="3069155" number="CN-105001151" title="Buparlisib intermediate and preparation method"/><PatentFamily id="3087224" number="WO-2017028802" title="Crystal form of 5-[2,6-di(4-morpholinyl)-4-pyrimidinyl]-4-(trifluoromethyl)-2-pyridinamine dihydrochloride and preparation method thereof"/><PatentFamily id="3203720" number="WO-2016092508" title="Treatment of breast cancer brain metastases"/><PatentFamily id="3314599" number="CN-105832758" title="Medicine composition for treating tumour and preparation method thereof"/><PatentFamily id="3314615" number="CN-105832741" title="Medicine composition of PI3k inhibitor and paclitaxel and application in preparing anti-tumour drug"/><PatentFamily id="3360043" number="WO-2016142508" title="Composition for treating pancreatic neuroendocrine tumours"/><PatentFamily id="3361132" number="US-09481665" title="Process for preparing pi3k inhibitor buparsilib"/><PatentFamily id="3387542" number="WO-2016151501" title="Pharmaceutical combinations"/><PatentFamily id="3417870" number="US-20160303137" title="Dual PI3K and Wnt pathway inhibition as a treatment for cancer"/><PatentFamily id="3444869" number="WO-2016182988" title="Compositions and methods for treatment of glioma"/><PatentFamily id="3471218" number="WO-2016193955" title="Combinations of kinase inhibitors for treating colorectal cancer"/><PatentFamily id="3625575" number="WO-2017077445" title="Dosage regimen for a phosphatidylinositol 3-kinase inhibitor"/><PatentFamily id="3660381" number="WO-2017093905" title="Treatment of cancer with a PI3K inhibitor in a patient preselected for having a PIK3CA mutation in the ctDNA"/><PatentFamily id="3745114" number="WO-2017132235" title="Methods for treating brain metastases using combinations of anti-PI3K and anti-mTOR agents"/><PatentFamily id="375496" number="WO-2010006225" title="Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of Ras/Raf/Mek pathway"/><PatentFamily id="3921061" number="WO-2018013534" title="Methods for treating pten deficient epithelial cancers using a combination of anti-PI3Kbeta and anti-immune checkpoint agents"/><PatentFamily id="3975225" number="WO-2018044906" title="Compositions and methods for treating cancer"/><PatentFamily id="639917" number="WO-2009109605" title="Use of pyrimidine derivatives for the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members"/><PatentFamily id="715728" number="WO-2007084786" title="Pyrimidine derivatives used as PI-3 kinase inhibitors"/><PatentFamily id="745395" number="WO-2012109423" title="Method of inhibiting hamartoma tumor cells"/><PatentFamily id="819231" number="WO-2009118324" title="Imidazoquinolines and pyrimidine derivatives as potent modulators of VEGF-driven angiogenic processes"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="10">Process</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="11">Process (Intermediate)</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="13">Product (derivative)</Type><Count>3</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="3">Component of Combination</Type><Count>29</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>4</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>6</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hospital Vall D'Hebron" id="1003065"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mitsubishi Chemical Holdings Corp" id="1022450"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Broad Institute Inc" id="1031693"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Ifo-Regina Elena Cancer Institute" id="1041458"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Crystal Pharmatech Co Ltd" id="1077753"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Medica Scientia Innovation Research" id="1084801"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Mirati Therapeutics Inc" id="1085701"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Suzhou MiracPharma Technology Co Ltd" id="1095700"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bausch Health Companies Inc" id="17058"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Johnson &amp; Johnson" id="17332"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard University" id="20584"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Indiana University" id="20593"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Massachusetts" id="20615"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Wistar Institute of Anatomy &amp; Biology" id="20944"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"/><CountAsOwner>4</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>4</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Texas System" id="21864"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Memorial Sloan-Kettering Cancer Center" id="22122"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Novartis AG" id="23137"/><CountAsOwner>26</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>26</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Texas A&amp;M University System" id="23290"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="UOP (Universal Oil Products) Inc" id="24831"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Harvard Medical School" id="24839"/><CountAsOwner>6</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>6</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Palermo" id="25176"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Centre Leon Berard" id="31154"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Fudan University" id="DOL1000375"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>